Yazd?r
T?rk
Toraks Derne?i ast?m tan? ve tedavi rehberi: Anahtar noktalar
F?sun YILDIZ1, ?. K?v?lc?m
O?UZ?LGEN2, Berna DURSUN3, Dil?ad MUNGAN4,
Bilun GEM?C?O?LU5,
Arzu YORGANCIO?LU6 ve T?rk Toraks Derne?i Ast?m ve Allerji ?al??ma
Grubu Ast?m Tan? ve
Tedavi Rehberi Komitesi*
1 Kocaeli
?niversitesi T?p Fak?ltesi, G???s Hastal?klar? Anabilim Dal?, Kocaeli,
2 Gazi
?niversitesi T?p Fak?ltesi, G???s Hastal?klar? Anabilim Dal?, Ankara,
3 SB
Atat?rk G???s Hastal?klar? ve G???s Cerrahisi E?itim ve Ara?t?rma Hastanesi,
Ankara,
4 Ankara
?niversitesi T?p Fak?ltesi, G???s Hastal?klar? Anabilim Dal?, Allerjik
Hastal?klar Bilim Dal?, Ankara,
5
?stanbul ?niversitesi ?stanbul T?p Fak?ltesi, G???s Hastal?klar? Anabilim Dal?,
?stanbul,
6 Celal Bayar
?niversitesi T?p Fak?ltesi, G???s Hastal?klar? Anabilim Dal?, Manisa.
* ?znur Abado?lu, ?lknur Ba?yi?it, Sevim
Bavbek, ?lk? Bay?nd?r, Hasan Bayram, ?smet Bulut, Berrin Ceyhan, Arif ??mr?n,
Haluk ?oku?ra?, Elif Da?l?, Berna Dursun, Dane Ediger, M?nevver Erdin?, Feyza
Erkan, Bilun Gemicio?lu, Nermin G?ler, A. Fuat Kalyoncu, B?lent Karada?, G?l
Karakaya, G?lbin Karako?, Emel Kurt, Zeynep M?s?rl?gil, Dil?ad Mungan, ?.
K?v?lc?m O?uz?lgen, Cans?n Sa?kesen, Necla Song?r, E. B?lent ?ekerel, Remziye
Tana?, Ayfer Tuncer, Haluk T?rkta?, ?pek T?rkta?, F?sun Y?ld?z, Arzu
Yorganc?o?lu, Hasan Y?ksel.
?ZET
T?rk Toraks Derne?i ast?m tan? ve
tedavi rehberi: Anahtar noktalar
Ast?m, d?nyada ve
?lkemizde patogenez, tan? ve tedavisinde t?m ilerlemelere ra?men morbiditesi ve
maliyeti y?ksek bir hastal?kt?r. Do?ru tan? ve tedavi ile kontrol alt?na
al?nabilen bir hastal?k olmas?na ra?men d?nyada ve ?lkemizde belirlenen d???k
kontrol oranlar? sadece hastal???n de?i?ken seyrine ve hastalar?n psikososyal
kronik hastal?k davran???na ba?lanamaz. Bu ba?lamda, T?rk Toraks Derne?i de en
son 2000 y?l?nda yay?nlad??? ?Ast?m Tan? ve Tedavi Rehberi?ni g?ncelleme karar?
alm??t?r. ?lkemizin verileri toplanm??, konu ile ilgili e?itimcilerden
olu?turulan yazarlar taraf?ndan kan?ta dayal? bilgiler derlenerek haz?rlanm??
ve T?rk Toraks Derne?i Ast?m ve Allerji ?al??ma Grubu taraf?ndan son ?ekli
verilerek, dan??man ki?i ve kurumlara sunulmu?tur. Haziran 2009 tarihinde T?rk
Toraks Derne?i ?Ast?m Tan? ve Tedavi Rehberi? T?rk?e olarak yay?nlanm??t?r. Bu
derlemede ulusal rehberin temel ?zellikleri ve di?erlerinden farklar? ?ngilizce
olarak sunulmaktad?r.
Anahtar Kelimeler: Ast?m,
tan?, tedavi, rehber.
SUMMARY
Turkish Thoracic Society asthma
management and prevention guideline: key points
F?sun YILDIZ1, ?. K?v?lc?m
O?UZ?LGEN2, Berna DURSUN3, Dil?ad MUNGAN4,
Bilun GEM?C?O?LU5,
Arzu YORGANCIO?LU6 and TTS Asthma and Allergy Working Group
Guideline Committee for
Asthma Diagnosis and Treatment*
1
Department of Chest Diseases, Faculty of Medicine, Kocaeli University, Kocaeli,
Turkey,
2
Department of Chest Diseases, Faculty of Medicine, Gazi University, Ankara,
Turkey,
3 Ataturk
Chest Disease and Chest Surgery Training and Research Hospital, Ankara, Turkey,
4
Division of Allergic Diseases, Department of Chest Diseases, Faculty of Medicine,
Ankara University,
Ankara, Turkey,
5
Department of Chest Diseases, Faculty of Istanbul Medicine, Istanbul
University, Istanbul, Turkey,
6 Department of
Chest Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey.
*?znur
Abado?lu, ?lknur Ba?yi?it, Sevim Bavbek, ?lk? Bay?nd?r, Hasan Bayram, ?smet
Bulut, Berrin Ceyhan, Arif ??mr?n, Haluk ?oku?ra?, Elif Da?l?, Berna Dursun,
Dane Ediger, M?nevver Erdin?, Feyza Erkan, Bilun Gemicio?lu, Nermin G?ler, A.
Fuat Kalyoncu, B?lent Karada?, G?l Karakaya, G?lbin Karako?, Emel Kurt, Zeynep
M?s?rl?gil, Dil?ad Mungan, ?. K?v?lc?m O?uz?lgen, Cans?n Sa?kesen, Necla
Song?r, E. B?lent ?ekerel, Remziye Tana?, Ayfer Tuncer, Haluk T?rkta?, ?pek
T?rkta?, F?sun Y?ld?z, Arzu Yorganc?o?lu, Hasan Y?ksel.
Asthma still has
high morbidity and cost despite all advances in pathogenesis, diagnosis and
treatment. Although asthma can be controlled with proper diagnosis and
treatment, the low rates of control in our country and in the world can not be
attributed to the variable course of the disease and patients? psycho-social
behaviours for chronic disease. In this context, Turkish Thoracic Society (TTS)
has decided to update Asthma Diagnosis and Management Guide latest published in
2000. National data were collected, compiled and prepared by authors, and final
form given by the TTS Asthma and Allergy Study Group, after presenting to
consultant individuals and institutions. In June 2009, the National Asthma
Management and Prevention Guideline were published in Turkish. In this paper,
we aimed to present the national guide in English with its basics and
individual differences.
Key Words: Asthma,
diagnosis, treatment, guideline.
DEFINITION
and EPIDEMIOLOGY
Asthma is a chronic
inflammatory disorder of the airways. The chronic inflammation is associated
with airway hyperresponsiveness that leads to recurrent episodes of wheezing,
breathlessness, chest tightness and coughing, particularly at night or in the
early morning. These episodes are usually associated with variable airflow
obstruction which is often reversible either spontaneously or with treatment
(1).
It is estimated
that asthma affect 300 million individuals in worldwide. Hundreds of reports on
the prevalence of asthma from different populations have shown wide range on
asthma prevalence. The global prevalence of asthma ranged from 1% to 18% (1).
In Turkey,
prevalence of asthma has important differences between cities and regions.
Asthma prevalence is higher in coastal regions, urban areas, metropolitan
cities and at lower socioeconomic conditions (2,3,4,5,6). There is an increase in
global prevalence, mortality and morbidity of asthma in last 30 years, but some
recent studies has showen that the prevalence of asthma tends to be stabilize
or even to decrease (7,8,9,10). The prevalence of asthma both in childhood and
adulthood in Turkey are shown in Table 1 and Table 2 (2,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25). Results of
national multicentered studies of Turkey are also shown in Table 3 (3,26,27,28).
Social and Economic
Burden
Asthma effects the
community not only economically but also socially. Asthma is an important cause
of absence from school and days lost from work all around the world. Thus,
mentioning the economic burden of asthma, it should cover both medical and
non-medical costs. Unfortunately, there is lack of data on this issue in
Turkey. In a prospective study including adult asthmatics from Ankara, the mean
annual total cost of asthma was found as 1467 ? 111.8 USD (29). Another study
from Ankara including childhood asthma patients showed that mean annual total
cost of asthma is 991.7 ? 73.2 USD (median: 688 USD) (30). A multicentered
childhood study from Turkey found that mean annual total cost of asthma is
1597.4 ? 236.2 USD (31). The authors also reported that the annual cost of asthma
is associated with unplanned doctor visits, hospitalization, asthma severity
and days lost from school. Adulthood asthma study also found similar results
(32).
RISK FACTORS
Factors influencing
the development and expression of asthma are well known and include both host
and environmental factors (1). In our published guide we mostly mentioned about
the findings of national studies.
Genetic Factors
Asthma has complex
heritable component. Multiple genes have roles in the pathogenesis of asthma
(1,33). There are four major areas for the genetic intervention: production of
allergen specific IgE antibodies, expression of airway hyperresponsiveness,
generation of inflammatory mediators and determination of the ratio between Th1
and Th2 immune responses (1,34).
Obesity
Obesity is another
risk factor for asthma. Leptin may involve in airway disfunction and developing
of asthma (1,34,35).
Gender
In early childhood
male sex is a risk factor for asthma. But as children get older the difference
between genders decrease and in adulthood prevalence of asthma is greater in
women than men (1,34,35,36).
Allergens
It is well known
that both indoor and outdoor allergen exposure can lead increase in asthma
symptoms, but their role in the development of asthma is still not clear (1,37,38).
Some studies shown that exposure to house dust mite may be a causal factor in
the development of asthma (39). It is also shown that exposure to cockroaches
is an important cause of sensitization (40,41). Some epidemiologic studies
found that early exposure to cats and dogs could protect against sensitization
or the development of asthma, but others suggested that those kinds of exposure
could increase the risk of sensitization (1). Children grown in rural areas
have less prevelance of asthma which could be explained by hygene hypothesis
(1,29,42).
Infections
The hygene
hypothesis suggests that infections in early life influence the child?s immune
system along a ?non-allergic? pathway, leading to a reduced risk of asthma and
other allergic diseases (1). However, the interaction between viral infections
and atopy is a complex situation.
Occupational
Sensitizers
Many substances
have been associated with occupational asthma. It is estimated that
occupational sensitizers cause approximately 10% of adult asthma cases.
Immunmediated occupational asthma with small molecules such as isocyanates has
a latency period of months to years. Irritant induced asthma (previoulsy named
reactive airways dysfunctional syndrome) occurs with intense exposure to
irritants (1,34).
Smoking
Smoking and/or
second hand smoke is associated with decline in lung function, increase in
symptoms and medication requirements, triggers asthma attacks (14,34). Both
prenatal and postnatal exposure to tobacco smoke lead asthma like symptoms in
early childhood (17,43). Recently, it is found that 11.4% of asthmatic patients
were smokers, which is lower than the percentage of smokers in the general
population of Turkey (44%) (44).
Outdoor/Indoor Air
Pollution
Although the role
of outdoor air pollution in causing asthma is still controversial, it is
obvious that asthma attacks increase with increased level of air pollution
(45). Indoor pollutants e.g., smoke and fumes from gas and biomass fuels,
molds, cockroach infestations are also related with triggered asthma symptoms
(1).
Diet
Breast-feeding is
the most studied subject in development of asthma. It is shown that infant fed
formulas of intact cow?s milk or soy protein have a higher incidence of
wheezing illness in early childhood compared with those fed by breast milk (3).
Some features of diet such as increased use of processed foods and decreased
antioxidant, increased n-6 polyunsaturated fatty acid, and decreased n-3
polyunsaturated fatty acid intakes may be related to increase in asthma (1,46).
DIAGNOSIS of ASTHMA
The most important
goal in order to be successful in asthma treatment is establishing a correct
diagnosis (1). Clinical history is very important and diagnosis of asthma is
prompted by episodic symptoms such as episodic breathlessness, wheezing and
chest tightness (47). Daytime and seasonal variability of symptoms, triggering
with fog, smoke, smell and exercise, increase at night and response to
appropriate asthma treatment support asthma diagnosis (34). A positive family
history of asthma and atopic diseases are also helpful diagnostic guides.
If the patient has
no symptoms the physical examination of the respiratory system may be normal
but asthma diagnosis can not be excluded. The most usual physical finding is
wheezing and ronchi on auscultation. Coughing at the end of each inspiration
during clinical and physical examination can be an indirect marker of bronchial
hyperresponsiveness and may lead clinician to think asthma diagnosis. In severe
asthma exacerbations wheezing and ronchi may be absent. However, patients in
this state usually have other physical signs reflecting severity, such as
cyanosis, drowsiness, difficulty in speaking, tachycardia, hyperinflated chest,
use of accessory muscles and intercostal retractions (1).
TESTS for DIAGNOSIS and FOLLOW UP
Asthma can often be
diagnosed on the basis of symptoms. However, measurement of lung function
supports the diagnosis by assessing the severity of airflow limitation,
reversibility and variability in lung function. Lung function test results in
normal ranges can not exclude the diagnosis of asthma. Although there was no
strong correlation between symptoms and control parameters with lung function
tests both in adults and children, these measurements provide descriptive
information for asthma control (48,49).
A wide range of
different methods to assess the level of airflow limitation exist, but two
methods have found widespread acceptance in patients over 5 years age. These
are the measurement of forced expiratory volume in 1 second (FEV1),
forced vital capacity (FVC) and measurement of peak expiratory flow (PEF). Any
FEV1/ FVC value less than 75% are suggestive of airflow limitation
(1,48). In a patient who has airflow obstruction a 12% or 200 mL improvement in
FEV1 in respect of basal value or a 20% improvement in PEF value
after the inhalation of short acting beta2 agonists (4 puff salbutamol= 400 ?g
or 4 puff terbutaline = 1000 ?g) indicates the early reversibility of airflow
obstruction (1,49,50).
Some of the airflow
obstructions have reversibility after 2-3 weeks oral corticosteroid (20-40
mg/day prednisolone) or 6-8 weeks appropriate dose inhaler corticosteroid
treatment. If there is a 15% increase in FEV1 value, this indicates
the late reversibility. Reversibility can not be found in patients who are
under treatment (1).
PEF
is still considered as an important aid in the diagnosis and subsequent
treatment of asthma (1). Ideally PEF should be first thing that measured in the
morning when values are usually close their lowest and last thing at night
after taking bronchodilator treatment when values are usually at their highest
(1). A diurnal variation in PEF of more than 20% is considered to be diagnostic
for asthma (1). Methods to measure PEF variablity are mentioned in the original
document (34).
For patients with
symptoms consistent with asthma, but with normal lung function, measurements of
airway hyperresponsiveness to methacholine, histamine, or exercise challenge
may help establishing a diagnosis of asthma (1,50,51,52).
The airway
inflammation associated with asthma may be evaluated by examining spontaneously
produced or induced sputum for total cell counts, eosinophils, neutrophils and
mediators (1,50,53,54). In addition levels of exhaled nitric oxide (NO) or
carbon monoxide (CO) have been suggested as non-invasive markers of airway
inflammation in asthma (1,50,55).
Evaluation
of allergic status in suspected patient from clinical history is skin prick
test. The test results should correlate with history in order to carry clinical
value. The standard allergens in a prick test examination are;
positive/negative control, grass polen, dermatofagoides pteronyssinus, cat and
alternaria allergens (38). Measurement of specific IgE is less sensitive and
more expensive. Measurement of total IgE in serum has no value as a diagnostic
test for atopy.
ASTHMA MEDICATIONS
The effectiveness
of drug therapy in asthma has been established for many years. The goal of
asthma treatment is to minimize symptoms with the fewest possible adverse effects.
The pharmaceutical agents used for asthma can be classified into two main
groups; relievers and controllers (1,34).
Available
controller medications in Turkey are inhaled glucocorticosteroids, leukotriene
receptor antagonists, long-acting β2-agonists, theophylline, anti-IgE
and systemic glucocorticosteroids. Available reliever medications are
rapid-acting inhaled β2-agonists, systemic glucocorticosteroids,
anticholinergics, theophylline, short-acting oral β2-agonists. And the
commonly available delivery systems are the metered dose inhaler (MDI), with or
without the use of a spacer, dry powder inhalers and nebulizers (56,57).
Clinical effects
and side effects for asthma medications are broadly given in Turkish Thoracic
Society Asthma Guideline (34).
Controller
Medications
Inhaler
corticosteroids (ICS) are the most effective controller therapy and must be
used continuously (58-64). Higher doses may be required for patients who smoke.
Adding a second controller medication is prefered to increasing the dose of ICS
(65,66). Common side effects of ICS are mentioned in the original document
(34,67,68,69,70,71,72,73,74,75,76,77,78). There is no evidence that use of inhaled glucocorticosteroids
increases the risk of pulmonary infections including tuberculosis (79,80).
Daily and equivalent doses of ICS available in Turkey are given in Table 4.
Leukotriene
Receptor Antagonists (LTRA), are mild bronchodilator and anti-inflammatory
drugs, used as an alternative treatment in mild persistent asthma, in some
patients with aspirin-sensitive asthma and exercise induced asthma. They can be
used as add-on therapy to reduce the dose of ICS required by patients with
moderate to severe asthma (81,82,83,84,85,86,87,88,89,90,91). They are effective not only in asthma but
also in patients with allergic rhinitis (92). Common side effects are mentioned
in the original document (34). Churg-Strauss syndrome associated with LTRA
treatment is accepted probably as the result of reductions in the doses of
systemic and/or inhaled glucocorticosteroids (93,94,95,96).
Long Acting 2
Agonists (LABA), should not be used as monotherapy in asthma. Clinical control
is achieved faster when they are added to ICS (97,98,99,100,101,102). Formoterol + budesonide
combination can be used as both reliever and controller therapy (103,104,105,106,107,108).
Common side effects are mentioned in the original document (34,109,110,111,112).
Theophylline, it is
a mild anti-inflammatory and mild bronchodilator agent. It can be added to ICS
if adequate control cannot be achieved with ICS, but less effective than LABA
(113,114,115,116,117,118,119,120). Common side effects are mentioned in the original document (34,121).
The principal
indication for anti-IgE treatment is uncontrolled severe, allergic asthma cases
under high doses of inhaled steroids and other controller therapies, with total
IgE level between 30-700 IU (1,122). Anti-IgE has steroid sparing affect and
improves asthma control in these selected group of asthmatics (123,124,125,126).
Long-term oral
glucocorticosteroid therapy (longer than two weeks) may be required for
severely uncontrolled asthma, but its use is limited by the risk of significant
adverse effects. The therapeutic index (effect/side effect) of long-term
inhaled glucocorticosteroids is always more favorable than long-term systemic
glucocorticosteroid therapy in asthma. Oral preparations are preferred over
parenteral (intramuscular or intravenous) for long-term therapy because of
their lower mineralocorticoid effect, relatively short half-life, and lesser
effects on striated muscle, and the greater flexibility of dosing that permits
titration to the lowest acceptable dose that maintains control (1,127,128).
Common side effects are well known and mentioned in the original document
(34,96,129,130,131,132,133).
Allergen specific
immunotherapy with clinically relevant allergens may be considered if disease
activity is inadequately controlled by avoidance of the allergens and
pharmacotherapy (1). Immunotherapy should be avoided when asthma is poorly
controlled. Neither should immunotherapy be initiated nor the dosage increased
during pregnancy. Common side effects are mentioned in the original document
(34).
Reliever
Medications
Rapid-acting
inhaled β2-agonists are for relief of bronchospasm during acute
exacerbations of asthma and for the pretreatment of exercise-induced asthma.
They include salbutamol and terbutaline. Because of its rapid onset of action
formoterol is also approved for symptom relief, but it should only be used for
patients on regular maintenance therapy with inhaled glucocorticosteroids (1).
Systemic
glucocorticosteroids are important in the treatment of severe acute
exacerbations because they prevent progression of the asthma exacerbation,
reduce the need for referral to emergency department and hospitalization,
prevent early relapse after emergency treatment, and reduce the morbidity of
the illness. Oral therapy is preferred and is as effective as intravenous
hydrocortisone (1). The main effects of systemic glucocorticosteroids in acute
asthma are evident after 4 to 6 hours. A typical short course of oral
glucocorticosteroids for an exacerbation is 30 mg prednisolone given daily for
5 to 10 days depending on the severity of the exacerbation.
Inhaled ipratropium
bromide for relief of bronchospasm is less effective than rapid-acting inhaled -agonists
in asthma. But it can be used together with an inhaled -agonist as it
shows statistically significant improvement in pulmonary function, and
significantly reduces the risk of hospital admission (1).
Short-acting
theophylline or aminophilline may provide no additive bronchodilator effect
over adequate doses of rapid-acting -agonists, but it may benefical for
stimulation of respiratory drive and diaphragmatic function (1).
The role of
complementary and alternative medicine in adult asthma treatment has not been
validated. They are not suggested for routine treatment of asthma in Turkey
(1,34).
ASSESSMENT, TREATMENT and MONITORING of
ASTHMA
Currently asthma
treatment is focused on disease control (1,50,133,134,135). ?Control? adjusted
asthma treatment has three domains: assessment of asthma control, treatment to
achieve control and monitoring to maintain control (1). In patients taking
controller medications, the level of asthma control will guide decisions either
to maintain or to adjust therapy (ie, step up if necessary, step down if
possible Asthma control levels and control assessment parameters used in the
national guideline are shown in Table 5 (1,34,136,137,138,139,140). In treatment naive
patient we recommend to begin treatment according to asthma severity (34,50).
Mild intermittent asthmatics should receive treatment from step 1 and as
severetiy increases initiation step should increase respectively. However the
follow-up should be done according to the asthma control (1,34,50).
Treatment steps to
achieve asthma control
Step 1:
As-needed reliever medication is used for occasional asthma symptoms. We
recommend the use of rapid acting inhaled 2-agonist as the first choice
(141).
Step 2: We
recommend the use of regular controller medication from this step on. The first
choice is low dose inhaler glucocorticosterids, alternative controller
medication include leukotriene receptor antagonists. Controller medications
should be combined with as needed reliever treatment (142,143,144,145).
Step 3: Low
dose of inhaled glucocorticosterids combined with a long-acting 2
agonist is the first treatment option (1). Medium dose inhaled
glucocorticosterids, low dose inhaled glucocorticosterids with a leukotriene
receptor antagonist or sustained release theophylline are alternate regimens
(135,146,147,148,149,150). All the regimens should be combined with as needed reliever
treatment. If a combination inhaler containing formoterol and budesonide is
selected, it may be used for both maintenance and reliever medication
(1,151,152,153,154). We emphasize the importance of using long acting β2 agonists
always with an inhaled glucocorticosteroids in asthma treatment.
Step 4:
Asthmatics who are not controlled on Step 3 should be referred to an
experienced centre for asthma management. First treatment option is medium dose
of inhaled glucocorticosterids combined with a long-acting 2 agonist
(135,146,155,156). In patients whom control can not be achieved with this
regimen a third drug like leukotriene receptor antagonist or sustained release
theophylline could be added to the treatment (1,157-159). If control is still
not achieved, then high dose of inhaled glucocorticosterids combined with a
long-acting 2 agonist is another option.
Step 5: This
step includes severe and hard to control asthmatics who need further evaluation
in an experienced centre for asthma management. Oral glucocorticosterids and
anti-IgE can help to achieve control in selected patients (160,161,162,163,164).
Ideally patients
must be assessed in four weeks periods till the asthma control is achieved.
Thereafter patients must be seen every three months (1). The medications should
be reduced until ?the minimum dose that maintains the control? is reached.
Stepping down the treatment should be tailored according to the patient?s
combination of medications and doses that were needed to achieve control.
We recommend the
following suggestions for stepping down the asthma therapy in whom the control
is achieved for at least three months (1,34):
In
patients using inhaled glucocorticosteroids alone, 50% dose reduction should be
introduced at three months intervals (165,166,167). If the control is achieved with
low dose inhaled glucocorticosteroids, once daily dosing can be administered
(168,169). If the patient is using combination therapy, the stepping down
strategy should begin with reducing the dose of inhaled glucocorticosteroids
(170). When the minimum dose of glucocorticosteroids is reached than the long
acting 2 agonist may be stopped. When the asthma remains
controlled for one year with the minimum dose of controller medicine,
controller therapy may be stopped. However patients must be closely monitored
for the recurrence of symptoms.
Treatment should be
stepped up in asthmatics that lose control. If repeated doses of rapid acting
β2 agonists do not achieve control, short course of oral
glucocorticosteroids or alternately four fold or greater increase in the dose
of inhaled glucocorticosteroids (for one to two weeks) can be administered
(171,172).
Difficult Asthma
Patients who do not
have any factors that makes it difficult to control their asthma and who need
two or more controller medications and high doses of inhaled
glucocorticosteroids (step 4 therapy) and still can not achieve asthma control
are considered as difficult asthmatics (1,173). These patients should be
referred to an experienced centre for asthma management.
IDENTIFY and REDUCE EXPOSURE to
RISK FACTORS
Pharmacologic
intervention to treat asthma is highly effective in controlling symptoms and
improving quality of life however measures to prevent the development of asthma
or asthma symptoms by avoiding or reducing exposure to risk factors should be
implemented when possible. Measures to prevent the development of asthma are
named as ?primary prevention?, where as efforts focusing on prevention of
asthma symptoms and attacks in patients with established asthma are called ?secondary
prevention? (34).
Few measures can be
recommended for primary prevention of asthma because the development of the
disease is complex and incompletely understood. The role of diet, prevention
strategies against inhalant allergens, methods towards reducing exposure to
house dust mites, exposure to cats, exposure to tobacco smoke, maternal smoking
during pregnancy are widely discussed in the original document (34,174,175,176,177,178,179,180,181,182,183,184,185).
There are
theoretical possibilities to avoid the development of asthma in subjects in
whom allergic sensitization has already occurred. Whether antihistamines can
prevent the development of asthma in children with atopic dermatitis remains an
area of investigation (186). Allergen specific immunotherapy has been shown to
decrease the risk of asthma development in later life in children with allergic
rhinitis (187). However these interventions cannot be recommended for wide
adoption in clinical practice at this time.
Asthma symptoms may
be caused by many factors including allergens, viral infections, pollutants and
drugs. Reducing a patient?s exposure to some of these triggers improves the
control of asthma and reduces medication needs. Allergens are important
environmental factors that can cause symptoms in the sensitized patient (34).
However there is conflicting evidence about whether measures to reduce exposure
to indoor allergens are effective at reducing asthma symptoms (34,188,189,190,191,192,193,194,195,196,197,198,199).
Several studies
have suggested that outdoor pollutants such as; ozone, nitrogen oxides, acidic
aerosols and particulate matters aggravate asthma symptoms. For patients with
asthma avoiding physical activity in cold weather and high air pollution are
practical recommendations for better control of the disease (200). The most
important measure in controlling indoor air pollutants is to avoid passive and
active smoking. A multicentered national study demonstrated a significant
relation between exposure to tobacco smoke and asthma symptoms (28,201).
Occupational
exposures account for a substantial proportion of adult asthma. The early
identification of occupational sensitizers and the removal of sensitized
patients from any further exposure are important aspects of the management of
occupational asthma (202). Routine influenza vaccination of patients with asthma
does not appear to protect them from exacerbations. The incidence of viral
upper respiratory infections was not different between vaccined and
non-vaccined asthmatic patients in a national study. However patients with
moderate to severe asthma should be advised to receive an influenza vaccination
every year or at least when vaccination of the general population is advised
(203,204).
ASTHMA EXACERBATIONS in ADULTS
Asthma exacerbation
is characterized by progressive increase in dyspnea, wheesing, chest tightness
accompanied by worsening of pulmonary functions. Two main factors are
responsible for an asthma exacerbation; inadequate antiinflammatory therapy and
being exposed to triggering factors (1,205,206,207,208,209,210).
The severity of
exacerbations can be determined according to the patient?s clinical
presentation, which includes breathlessness, talking pattern, alertness,
respiratory rate, accessory muscle retractions, wheezing, pulsus paradoxus,
PEF, PaO2, PaCO2 and SaO2 values. Severity is
classified into four categories: mild, moderate, severe and life threatening
(1,211,212). We emphasized that severity of asthma should not be underestimated
as it can be potentially life threatening. Patients who have risk factors for
life threatening asthma exacerbations should be encouraged to admit to a
physician without delay and should carefully be monitored in emergency setting.
These are asthmatics shown in Table 6 (1,50,207,213,214,215,216,217).
Management of
Exacerbations
We recommend home
management in mild-moderate exacerbations. However, severe exacerbations should
be managed in emergency settings (34).
Home management of
exacerbations includes recurrent use of short acting β2 agonists (high
doses preferably with a spacer) and systemic glucocorticosteroids
(1,34,50,215,217,218,219,220,221).
Patient with a
severe exacerbation admitted to emergency department should be evaluated
promptly. Oxygen therapy (to achieve SaO2> 90%), rapid acting
β2 agonists (nebulized or given with a spacer) at regular and short
intervals should be administered (1,34,50,213,215,219,221,222,223). Further
bronchodilation can be achieved with combination of ipratropium with salbutamol
(224,225,226). Systemic glucocorticosteroids should be administered orally or
intravenously as they accelerate the resolution of exacerbation (0.5 mg/kg for
7-10 days) (1,34,50,227,228,229).
We recommend the
use of intravenous magnesium sulphate infusion, intravenous theophylline
infusion consecutively as further therapies (1,50,219,230,231). Detailed list
and dosing of medications used in exacerbations are mentioned in the original
document (34).
Intensive care unit
therapy and mechanical ventilation: Indications for
hospitalization in intensive care and mechanical ventilation are (1):
? Poor response to
initial therapy at emergency care or worsening of exacerbation,
? Respiratory
insufficiency despite oxygen support (PaO2 < 60 mmHg and/or PaCO2
> 45 mmHg),
? Confusion,
cyanosis and severe symptoms,
? Cardiac
and respiratory arrest.
Non-invasive
mechanical ventilation can be administered in selected cases (1).
Patients
can be discharged if their symptoms are under control in the last 24 hours with
their prescribed home therapy. Inhaler glucocorticosteroids should not be
discontinued during the exacerbation. If the patient was not on an inhaler
glucocorticosteroid before exacerbation, it should be prescribed before
discharge. Systemic glucocorticosteroids should not be discontinued before 7-10
days. Patients should be referred to an asthma specialist after discharge
(1,211,221,232,233,234,235,236).
SPECIAL CONSIDERATIONS
Pregnancy; surgery;
rhinitis, sinusitis and nasal polyps; occupational asthma, respiratory
infections, gastroesophageal reflux and aspirin-induced asthma need to be
considered as special considerations.
Asthma and
Pregnancy
The
most common respiratory system disorder during pregnancy is asthma (4-7%).
Pregnancy effects the natural course of asthma as well as asthma can effect
pregnancy and delivery. In approximately one-third of women asthma becomes
worse; in one-third asthma becomes less severe; and in the other one-third it
remains unchanged during pregnancy (1,237,238). Poorly controlled asthma can
have an adverse effect on pregnancy may cause maternal and fetal complications
(1,50,51,237,238). Asthma control during pregnancy is very important for both
mother and the baby.
Using medications
to obtain optimal control of asthma is justified even when their safety in
pregnancy has not been proven. For most drugs used to treat asthma there is
little evidence to suggest an increased risk to the fetus. Inhaled
glucocorticosteroids (ICSs), β2-agonists, leukotriene receptor
antagonists, specifically montelukast and appropriately monitored theophylline,
are not associated with an increased incidence of fetal abnormalities. ICSs
have been shown to prevent exacerbations of asthma in pregnancy. Acute
exacerbations should be treated aggressively in order to avoid fetal hypoxia
(34).
Delivery will not
be different than the non-asthmatics, special consideration should be given to
analgesia. Asthmatic mother could breat feed her baby while using her medications
(51,238).
Surgery
Asthmatic patients
are prone to intraoperative and postoperative respiratory complications due to
their airway hyperresponsiveness, limitation, and mucus hypersecretion. These
complications may change depending on the severity of asthma at the time of
surgery, the type of surgery (thoracic and upper abdominal pose the greatest
risks), and type of anesthesia (general anesthesia with endotracheal intubation
carries the greatest risk). A careful and detailed evaluation should be undertaken
several days prior to surgery and pulmonary function should be measured. If FEV1
value is less than 80 percent of the patient?s personal best, a short course of
glucocorticosteroids should be considered. Furthermore, patients who have
received systemic glucocorticosteroids within the past 6 months should have
systemic coverage during the surgical period (100 mg hydrocortisone every 8
hours intravenously) and rapidly reduced 24 hours following surgery (1,50,51,238).
Rhinitis, Sinusitis
and Nasal Polyps
Upper airway
diseases can influence lower airway function. Although the mechanisms
associated with this relationship are not established, inflammation likely
plays a similarly critical role in the pathogenesis of rhinitis, sinusitis, and
nasal polyps, as seen in asthma.
Asthma
and rhinitis often coexist in the same patient (50,92). The majority (like 75
%) of patients with asthma have a history or evidence of rhinitis and rhinitis
frequently precedes the development of asthma (92). Treatment of rhinitis may
improve asthma symptoms. Anti-inflammatory agents including
glucocorticosteroids, leukotriene modifiers, and anticholinergics can be
effective in both conditions (50,92,239).
Both acute and
chronic sinusitis can worsen asthma. (92,240,241). Topical nasal decongestants
or topical nasal or even systemic glucocorticosteroids should be used to reduce
nasal congestion (1,50,92).
Nasal polyps
associated with asthma and rhinitis are often accompanied with aspirin
sensitivity (92). Between 36% and 96% of aspirin-intolerant patients have
polyps and 29% to 70% percent of patients with nasal polyps may have asthma.
Nasal polyps respond well to topical corticosteroids, surgery could be
considered in non-responders (1,242,243,244).
Occupational Asthma
More than 400 causative
agents for occupational asthma have been reported from developed countries
(1,238). Recording on occupational diseases has been started in Turkey since
1970 and various occupational exposures have been reported (245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273). Symptoms
and air flow limitation while at work and improvement outside the work will
lead the diagnosis (34). Spirometric confirmation such as PEF meter follow-up
is necessary for legal procedures with a sensitivity of 70-80% and specifity of
85-90%. Gold standard is specific bronchoprovocation but it could only be
performed in special centers (50,51,238). Once diagnosed, complete avoidance of
the relevant exposure is an important component of management. Continued
exposure may lead to severe and potentially fatal asthma exacerbations and
permanently impaired lung function. Medical treatment is not different than
asthma (50,51,238).
Respiratory
Infections
Viral and rarely
bacterial infections of respiratory tract may increase symptoms and trigger
exacerbations in asthmatics (274,275,276). As increased asthma symptoms often last
for weeks beyond the infection, anti-inflammatory treatment should be continued
for weeks to ensure adequate control (277,278,279).
Gastroesophageal
reflux (GER), is nearly three times as prevalent in all patients with asthma in
comparison to the general population (280,281). Most of these patients also
have a hiatal hernia; furthermore, theophylline and oral β2-agonists may
increase the likelihood of symptoms by relaxing the lower esophageal ring.
Patients who are not well controlled with appropriate medical treatment should
be evaluated and if necessary treated for GER (282,283,284,285,286,287,288).
Aspirin-Induced
Asthma (AIA) is often together with rhinosinusitis, nasal polyp and aspirin
intolerance (289). The majority of patients first experience symptoms during
the third or fourth decade of life, which may include vasomotor rhinitis and
profuse rhinorrhea. Chronic nasal congestion evolves, and physical examination
often reveals nasal polyps. Asthma and intolerance to aspirin often develop
subsequently. The intolerance itself presents a unique picture: within an hour
following ingestion of aspirin, an acute, often severe asthma exacerbation
develops, which may be accompanied by rhinorrhea, conjunctival irritation, and
scarlet flush of the head and neck. Indeed, a single aspirin or other
cyclooxygnease inhibitor can provoke violent bronchospasm, shock, loss of
consciousness, and respiratory arrest (1,243,290,291,292,293). Although a patient's
clinical history may raise suspicion of AIA, the diagnosis is only established
by aspirin challenge, conducted in facilities where cardiopulmonary
resuscitation capabilities exist. Patients with AIA should avoid aspirin,
products containing it, and other analgesics that inhibit cyclooxygenase and
hydrocortisone hemisuccinate. Glucocorticosteroids continue to be the mainstay
of therapy, while leukotriene modifiers may be useful for additional control of
the underlying disease (294,295,296,297,298,299,300,301,302,303,304,305,306,307,308).
CONFLICT of? INTEREST
None declared.
REFERENCES
-
Global
Strategy for asthma management and prevention. 2009 (update) www.ginasthma.org
-
Braman
SS. The global burden of asthma. Chest 2006; 130: 4S-12S.
[?zet] [Tam Metin] [PDF]
-
Demir
AU, Karakaya G, Bozkurt B, Sekerel BE, Kalyoncu AF. Asthma and allergic
diseases in schoolchildren: third cross-sectional survey in the same primary
school in Ankara, Turkey. Pediatr Allergy Immunol 2004; 15: 531-38.
[?zet]
-
Demir
E, Tanac R, Can D, Gulen F, Yenigun A, Aksakal K. Is there an increase in the
prevalence of allergic diseases among schoolchildren from the Aegean region of
Turkey. Allergy Asthma Proc 2005; 26: 410-4.
[?zet]
-
Ones
U, Akcay A, Tamay Z, Guler N, Zencir M. Rising trend of asthma prevalence among
Turkish school children (ISAAC phases I and III). Allergy 2006; 61: 1448-53.
[?zet] [Tam Metin] [PDF]
-
Bayram
I, Guneser-Kendirli S, Yilmaz M, Altintas DU, Alparslan N, Bingol-Karakoc G.
The prevalence of asthma and allergic diseases in children of school age in
Adana in Southern Turkey. Turk J Pediatr 2004; 46: 221-5.
[?zet]
-
Saraclar
Y, Kuyucu S, Tuncer A, Sekerel BS, Sackesen C, Kocabas C. Prevalence of
asthmatic phenotypes and bonchial hyperresponsiveness in Turkish
schoolchildren: an International Study of Asthma and Allergies in Childhooh
(ISAAC) phase 2 study. Ann Allergy Asthma Immunol 2003; 91: 477-84.
[?zet]
-
Von
Mutius E. The rising trends in asthma and allergic disease. Clin Exp Allergy
1998; 28(Suppl 5): S45-9.
[?zet]
-
Sensthilselvan
A, lawson J, Rennie DC, Dosman JA. Stabilization of an increasing trend in
physician-diagnosed asthma prevalence in Saskatchewan, 1991 to 1998. Chest
2003; 124: 438-48.
[?zet] [Tam Metin] [PDF]
-
Akinbami
LJ, Schoendorf KC. Trends in childhood asthma: prevalence, health care
utilization, and mortality. Pediatrics 2002; 110(2Pt 1): 315-22.
[?zet]
-
Von
HertzenL, Haahtela T. Signs of reversing trends in prevalence of asthma.
Allergy 2005; 60: 283-92.
[?zet] [Tam Metin] [PDF]
-
Akcakaya
N, Kulak K, Hassanzadeh A, Camcioglu Y, Cokugras H. Prevalence of bronchial
asthma and allergic rhinitis in Istanbul school schildren. Eur J Epidemiol
2000; 16: 693-9.
[?zet]
-
Kendirli
GS, Altintas DU, Alparslan N, Akmanlar N, Yurdakul Z, Bolat B. Prevalence of
childhood allergic diseases in Adana, Southern Turkey. Eur J Epidemiol 1998;
14: 347-50.
[?zet]
-
Selcuk
ZT, Caglar T, Enunlu T, Topal T. The prevalence of allergic diseases in primary
school children in Edirne, Turkey. Clin Exp Allergy 1997; 27: 262-9.
[?zet]
-
Unlu
M, Orman A, Dogan N. The prevalence of asthma among secondary school students
in Afyon, Turkey. Asian Pac J Allergy Immunol 2002; 20: 1-6.
[?zet]
-
Ece
A, Ceylan A, Saraclar Y, Saka G, Gurkan F, Haspolat K. Prevalence of asthma and
other allergic diseases among school children in Diyarbakir, Turkey. Turk J
Pediatr 2001; 43: 286-92.
[?zet]
-
Alper
Z, Sapan N, Ercan I, Canitez Y, Bilgel N. Risk factors for wheezing in primary
school children in Bursa, Turkey. Am J Rhinol 2006; 20: 53-63.
[?zet]
-
Karaman
O, Turgut CS, Uzuner N, Olmez D, Babayigit A, Kose S, Tezcan D. The
determination of asthma, rhinitis, eczema, and atopy prevalence in 9- to
11-year-old children in the city of Izmir. Allergy Asthma Proc 2006; 27:
319-24.
[?zet]
-
Zeyerk
CD, Zeyrek F, Sevinc E, Demir E. Prevalence of asthma and allergic diseases in
Sanliurfa, Turkey, and the relation to environmental and socioeconomic factors:
is the hygiene hypothesis enough? J Investig Allergol Clin Immunol 2006; 16:
290-5.
[?zet] [PDF]
-
Tomac
N, Demirel F, Acun C, Ayoglu F. Prevalence and risk factors for childhood
asthma in Zonguldak, Turkey. Allergy Asthma Proc 2005; 26: 397-402.
[?zet]
-
Ozdemir
N, Ucgun I, Metintas S, Kolsuz M, Metintas M. The prevalence of asthma and
allergy amoung university freshmen in Eskisehir, Turkey. Respir Med 2000; 94:
536-41.
[?zet]
-
Celik
G, Mungan D, Bavbek S, et al. The prevalence of allergic diseases and atopy in
Ankara, Turkey: a two-step population based epidemiological study. J Asthma
1999; 36: 281-90.
[?zet]
-
Tug
T, Acik Y. Prevalence of asthma, asthma-like and allergic symptoms in the urban
and rural adult population in Eastern Turkey. Asian Pac J Allergy Immunol 2002;
20: 209-11.
[?zet]
-
Akkurt
I, Sumer H, Ozsahin SL, Gonlugur U, Ozdemir L, Dogan O, et al. Prevalence of
asthma and related symptoms in Sivas, Central Anatolia. J Asthma 2003; 40:
551-6.
[?zet]
-
Dinmezel
S, Ogus C, Erengin H, Cilli A, Ozbudak O, Ozdemir T. The prevalence of asthma,
allergic rhinitis and atopy in Antalya, Turkey. Allergy Asthma Proc 2005; 26:
403-9.
[?zet]
-
Sakar
A, Yorgancioglu A, Dinc G, Yuksel H, Celik P, Dagyildizi L, et al. The
prevalence of asthma and allergic symptoms in Manisa, Turkey. Asian Pac J
Allergy Immunol 2006; 24: 17-25.
[?zet]
-
Turktas
I, Selcuk ZT, Kalyoncu AF. Prevalence of asthma-associated symptoms in Turkish
children. Turk J Pediatr 2001; 43: 1-11.
[?zet]
-
Kurt
E, Metintas S, Basyigit I, Bulut I, Coskun E, Dabak S, et al. Prevalence and
risk factors of allergies in Turkey: results of a multicentric cross-sectional
study in children. Pediatr Allergy Immunol 2007; 18: 566-74.
[?zet]
-
Kurt
E, Metinta? S, Basyigit I, Bulut I, Coskun E, Dabak S, et al. Prevalence and
risk factors of allergies in Turkey (PARFAIT): results of a multicentre
cross-sectional study in adults. Eur Respir J 2009; 33: 724-33.
[?zet] [Tam Metin] [PDF]
-
Celik
GE, Bavbek S, Pasaoglu G, Mungan D, Abado?lu O, Harmanci E, et al. Direct
medical cost of asthma in Ankara, Turkey. Respiration 2004; 71: 587-93.
[?zet]
-
Beyhun
NE, Cilingiroglu N, Sekerel BE. The cost of childhood asthma and its
determinants in Ankara, Turkey. Turk J Pediatr 2007; 49: 179-88.
[?zet]
-
Beyhun
NE, Soyer OU, Kuyucu S, Yildirim S, Boz AB, Altinel N, et al. A multi-center
survey of childhood asthma in Turkey - I: the cost and its determinants.
Pediatr Allergy Immunol 2009; 20: 72-80.
[?zet] [Tam Metin] [PDF]
-
Sackesen
C, Karaaslan C, Keskin O, Tokol N, Tahan F, Civelek E, et al. The effect of
polymorphisms at the CD14 promoter and the TLR4 gene of asthma phenotypes in
Turkish children with asthma. Allergy 2005; 60: 1485-92.
[?zet] [Tam Metin] [PDF]
-
T?rk
Toraks Derne?i Ast?m Tan? ve Tedavi rehberi. Turkish Thoracic Journal 2009;
10(Suppl 9): S1-75 .
-
Guler
N, Kirerli E, Ones U, Tamay Z, Salmayenli N, Darendeliler F. Leptin: does it
have any role in childhood asthma? J Allergy Clin Immunol 2004; 114: 254-9.
[?zet]
-
Sekerel
BE, Civelek E, Karabulut E, Yildirim S, Tuncer A, Adalioglu G. Are risk factors
of childhood asthma predicting disease persistence in early adulthood different
in the developing world? Allergy 2006; 61: 869-77.
[?zet] [Tam Metin] [PDF]
-
Mungan
D, Celik G, Bavbek S, Misirligil Z. Pet allergy: how important for Turkey where
there is a low pet ownership rate. Allergy Asthma Proc 2003; 24: 137-42.
[?zet]
-
Kalyoncu
AF, Coplu L, Selcuk ZT, Emri AS, Kolacan B, Kocabas A, et al. Survey of the
allergic status of patients with bronchial asthma in Turkey: a multicentric
study. Allergy 1995: 5: 451-5.
[?zet]
-
Akcakaya
N, Cokugras H, Camcioglu Y, Ozdemir M. Skin test hypersensitivity for childhood
asthma in ?stanbul during a period of 16 years. Allergol Immunopathol 2005; 33:
15-9.
[?zet]
-
Mungan
D, Celik G, Sin B, Bavbek S, Demirel Y, Misirligil Z. Characteristic features
of cockroaches sensitivity in Turkish asthmatic patients. Allergy 1998; 53:
870-3.
[?zet]
-
Uzel
A, Capan N, Canbakan S, Yurdakul AS, Dursun B. Evaluation of the relationship
between cockroach sensitivity and house-dust sensitivity in Turkish asthmatic
patients. Respir Med 2005; 99: 1032-7.
[?zet]
-
Celik
G, Sin B, Keskin S, Ediger D, Bavbek S, Mungan D, et al. Risk factors
determining allergic airway diseases in Turkish subjects. J Asthma 2002;
383-90.
[?zet]
-
Kalyoncu
AF, Demir AU, Ozcakar B, Bozkurt B, Artvinli M. Asthma and allergy in Turkish
university students: two cross-sectional surveys 5 years apart. Allergol
Immunopathol (Madr) 2001; 29: 264-71.
[?zet]
-
Yildiz
F, Ozesen C, Disci R and PASTE study group. Prevalance of asthmatic smokers:
Turkish experience (PASTE study). J Asthma (in press).
-
Bayram
H, Dikensoy O. Air pollution and its effects on pulmonary health. Tuberk Toraks
2006; 54: 80-9.
[?zet] [PDF]
-
Devereux
G, Seaton A. Diet as a risk factor for atopy and asthma. J Allergy Clin Immunol
2005; 115: 1109-17.
[?zet]
-
Levy
ML, Fletcher M, Price DB, Hausen T, Halbert RJ, Yawn BP. International Primary
Care Respiratory Group (IPCRG) Guidelines: diagnosis of respiratory diseases in
primary care. Prim Care Respir J 2006; 15: 20-34.
[?zet] [PDF]
-
Kerstjens
HA, Brand PL, de Long PM, Koeter GH, Postma DS. Influence of treatment on peak
expiratory flow and its relationn to airway hyperresponsiveness and symptoms.
The Dutch CNSLD Study Group. Thorax 1994; 49: 1109-15.
[?zet] [PDF]
-
Pellegrino
R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative
strategies for lung function tests. Eur Respir J 2005; 26: 948-68.
[?zet] [Tam Metin] [PDF]
-
Expert
Panel Report 3 (EPR-3): Guidelines fort he diagnosis and management of
asthma-Full Report 2007. J Allergy Clin Immunol 2007; 120: 94-138.
[?zet]
-
The
National Asthma Council Australia. Asthma Management Handbook and updated 2006.
-
Karaa?a?
G, ?elik N, Ba?l?lar S, Y?lmaz T. Diffences in response to direct and indirect
stimulus in asthma. Toraks Dergisi 2003; 4: 161-7.
[?zet] [Tam Metin] [PDF]
-
Karakurt
Z, Ceyhan B, Karakurt S, Turker H. Induced sputum cell profile in mild to
severe stable asthmatics and healthy adults. Turkish Respiratory Journal 2001;
2: 22-7.
-
Yildiz
F, Basyigit F, Boyaci H, Ilgazli A, Ozkara S. Comparison of induced cell counts
in COPD and asthma. Turkish Respiratory Journal 2003; 4: 43-6.
-
O?uz?lgen
K, T?rkta? H, Erba? D. Factors effecting the exhaled nitric oxide levels in
stable asthmatics. Toraks Dergisi 2002; 3: 232-5.
[?zet] [Tam Metin] [PDF]
-
Brown
PH, Greening AP, Crompton GK. Large volume spacer devices and the influence of
high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis
function. Thorax 1993; 48: 233-8.
[?zet] [PDF]
-
Lewis
DA, Ganderton D, Meakin BJ, Brambilla G. Modulite: a simple solution to a
difficult problem. Respiration 2005; 72 (Suppl 1): 3-5.
[?zet]
-
Juniper
EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of
long-term treatment with an inhaled corticosteroid (budesonide) on airway
hyperresponsiveness and clinical asthma in nonsteroiddependent asthmatics. Am
Rev Respir Dis 1990; 142: 832-6.
[?zet]
-
Long-term
effects of budesonide or nedocromil in children with asthma. The Childhood
Asthma Management Program Research Group. N Engl J Med 2000; 343: 1054-63.
[?zet] [Tam Metin] [PDF]
-
Jeffery
PK, Godfrey RW, Adelroth E, Nelson F, Rogers A, Johansson SA. Effects of
treatment on airway inflammation and thickening of basement membrane reticular
collagen inasthma. A quantitative light and electron microscopic study. Am Rev
Respir Dis 1992; 145(4 Pt 1): 890-9.
[?zet]
-
Pauwels
RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect
of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and
Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl
J Med 1997; 337: 1405-11.
[?zet] [Tam Metin] [PDF]
-
Suissa
S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and
the prevention of death from asthma. N Engl J Med 2000; 343: 332-6.
[?zet] [Tam Metin] [PDF]
-
Waalkens
HJ, Van Essen-Zandvliet EE, Hughes MD, Gerritsen J, Duiverman EJ, Knol K, et
al. Cessation of longterm treatment with inhaled corticosteroid (budesonide) in
children with asthma results in deterioration. The Dutch CNSLD Study Group. Am
Rev Respir Dis 1993; 148: 1252-7.
[?zet]
-
Jayasiri
B, Perera C. Successful withdrawal of inhaled corticosteroids in childhood
asthma. Respirology 2005; 10: 385-8.
[?zet]
-
Powell
H, Gibson PG. Inhaled corticosteroid doses in asthma: an evidence-based
approach. Med J Aust 2003; 178: 223-5.
[?zet]
-
Szefler
SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al.
Significant variability in response to inhaled corticosteroids for persistent asthma.
J Allergy Clin Immunol 2002; 109: 410-8.
[?zet]
-
Lipworth
BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic
review and meta-analysis. Arch Intern Med 1999; 159: 941-55.
[?zet] [Tam Metin] [PDF]
-
Barnes
PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998;
102(4 Pt 1): 531-8.
[?zet]
-
Kamada
AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JM, et al. Issues
in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Am
J Respir Crit Care Med 1996; 153(6 Pt 1): 1739-48.
-
Lee
DK, Bates CE, Currie GP, Cowan LM, McFarlane LC, Lipworth BJ. Effects of
high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal
axis in asthmatic patients with severely impaired lung function. Ann Allergy
Asthma Immunol 2004; 93: 253-8.
[?zet]
-
Mak
VH, Melchor R, Spiro SG. Easy bruising as a side-effect of inhaled
corticosteroids. Eur Respir J 1992; 5: 1068-74.
[?zet]
-
Lung
Health Study Research Group. Effect of inhaled triamcinolone on the decline in
pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;
343: 1902-9.
[?zet] [Tam Metin] [PDF]
-
Pauwels
RA, Yernault JC, Demedts MG, Geusens P. Safety and efficacy of fluticasone and
beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group.
Am J Respir Crit Care Med 1998; 157(3 Pt 1): 827-32.
[?zet] [Tam Metin] [PDF]
-
Ernst
P, Baltzan M, Deschenes J, Suissa S. Low-dose inhaled and nasal corticosteroid
use and the risk of cataracts. Eur Respir J 2006; 27: 1168-74.
[?zet] [Tam Metin] [PDF]
-
Cumming
RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of
cataracts. N Engl J Med 1997; 337: 8-14.
[?zet] [Tam Metin] [PDF]
-
Garbe
E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the
risks of ocular hypertension or openangle glaucoma. JAMA 1997; 277: 722-7.
[?zet]
-
Agertoft
L, Larsen FE, Pedersen S. Posterior subcapsular cataracts, bruises and
hoarseness in children with asthma receiving long-term treatment with inhaled
budesonide. Eur Respir J 1998; 12: 130-5.
[?zet] [PDF]
-
Toogood
JH, Markov AE, Baskerville J, Dyson C. Association of ocular cataracts with
inhaled and oral steroid therapy during long-term treatment of asthma. J
Allergy Clin Immunol 1993; 91: 571-9.
[?zet]
-
Simons
FE, Persaud MP, Gillespie CA, Cheang M, Shuckett EP. Absence of posterior
subcapsular cataracts in young patients treated with inhaled glucocorticoids.
Lancet 1993; 342: 776-8.
[?zet]
-
Bahceciler
NN, Nuhoglu Y, Nursoy MA, Kodalli N, Barlan IB, Basaran MM. Inhaled
corticosteroid therapy is safe in tuberculin-positive asthmatic children.
Pediatr Infect Dis J 2000; 19: 215-8.
[?zet]
-
Dicpinigaitis
PV, Dobkin JB, Reichel J. Antitussive effect of the leukotriene receptor
antagonist zafirlukast in subjects with cough-variant asthma. J Asthma 2002;
39: 291-7.
[?zet]
-
Lipworth
BJ. Leukotriene-receptor antagonists. Lancet 1999; 353: 57-62.
[?zet]
-
Drazen
JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the
leukotriene pathway. N Engl J Med 1999; 340: 197-206.
-
Barnes
NC, Miller CJ. Effect of leukotriene receptor antagonist therapy on the risk of
asthma exacerbations in patients with mild to moderate asthma: an integrated
analysis of zafirlukast trials. Thorax 2000; 55: 478-83.
[?zet] [Tam Metin] [PDF]
-
Noonan
MJ, Chervinsky P, Brandon M, Zhang J, Kundu S, McBurney J, et al. Montelukast,
a potent leukotriene receptor antagonist, causes dose-related improvements in
chronic asthma. Montelukast Asthma Study Group. Eur Respir J 1998; 11: 1232-9.
[?zet] [PDF]
-
Reiss
TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast,
a once-daily leukotriene receptor antagonist, in the treatment of chronic
asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical
Research Study Group. Arch Intern Med 1998; 158: 1213-20.
[?zet] [Tam Metin] [PDF]
-
Leff
JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a
leukotriene-receptor antagonist, for the treatment of mild asthma and
exerciseinduced bronchoconstriction. N Engl J Med 1998; 339: 147-52.
[?zet] [Tam Metin] [PDF]
-
Dahlen
B, Nizankowska E, Szczeklik A, Zetterstrom O, Bochenek G, Kumlin M, et al.
Benefits from adding the 5- lipoxygenase inhibitor zileuton to conventional
therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157:
1187-94.
[?zet] [Tam Metin] [PDF]
-
Laviolette
M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, et al. Montelukast
added to inhaled beclomethasone in treatment of asthma.
Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999;
160: 1862-8.
[?zet] [Tam Metin] [PDF]
-
Lofdahl
CG, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF, et al. Randomised, placebo
controlled trial of effect of a leukotriene receptor antagonist, montelukast,
on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319:
87-90.
[?zet] [Tam Metin] [PDF]
-
Virchow
JC, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma
control in patients receiving highdose inhaled corticosteroids. Am J Respir
Crit Care Med 2000; 162(2 Pt 1): 578-85.
[?zet] [Tam Metin] [PDF]
-
Bousquet
J, Khaltaev N, Cruz AA, et al; World Health Organization; GA(2)LEN; AllerGen.
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration
with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;
63(Suppl 86): S8-160.
-
Wechsler
ME, Finn D, Gunawardena D, Westlake R, Barker A, Haranath SP, et al.
Churg-Strauss syndrome in patients receiving montelukast as treatment for
asthma. Chest 2000; 117: 708-13.
[?zet] [Tam Metin] [PDF]
-
Wechsler
ME, Pauwels R, Drazen JM. Leukotriene modifiers and Churg-Strauss syndrome:
adverse effect or response to corticosteroid withdrawal? Drug Saf 1999; 21:
241-51.
[?zet]
-
Harrold
LR, Andrade SE, Go AS, Buist AS, Eisner M, Vollmer WM, et al. Incidence of Churg-Strauss
syndrome in asthma drug users: a population-based perspective. J Rheumatol
2005; 32: 1076-80.
[?zet]
-
Kalyoncu
AF, Karakaya G, Sahin A, Artvinli M. Experience of 10 years with Churg-Strauss
syndrome: An accompaniment to or a transition from aspirin-induced asthma?
Allergol Immunopathol 2001; 29: 185-90.
[?zet]
-
Lemanske
RF Jr, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, et al. Inhaled
corticosteroid reduction and elimination in patients with persistent asthma
receiving salmeterol: a randomized controlled trial. JAMA 2001; 285: 2594-603.
[?zet] [Tam Metin] [PDF]
-
Lazarus
SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF Jr, Sorkness CA, et al.
Long-acting beta2-agonist monotherapy vs. continued therapy with inhaled
corticosteroids in patients with persistent asthma: a randomized controlled
trial. JAMA 2001; 285: 2583-93.
[?zet] [Tam Metin] [PDF]
-
Pearlman
DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, et al. A
comparison of salmeterol with albuterol in the treatment of mild-to-moderate
asthma. N Engl J Med 1992; 327: 1420-5.
[?zet] [Tam Metin] [PDF]
-
Kesten
S, Chapman KR, Broder I, Cartier A, Hyland RH, Knight A, et al. A three-month
comparison of twice daily inhaled formoterol versus four times daily inhaled
albuterol in the management of stable asthma. Am Rev Respir Dis 1991; 144 (3 Pt
1): 622-5.
[?zet]
-
Wenzel
SE, Lumry W, Manning M, Kalberg C, Cox F, Emmett A, et al. Efficacy, safety,
and effects on quality of life of salmeterol versus albuterol in patients with
mild to moderate persistent asthma. Ann Allergy Asthma Immunol 1998; 80:
463-70.
[?zet]
-
Stoloff
SW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig JR. Improved refill
persistence with fluticasone propionate and salmeterol in a single inhaler
compared with other controller therapies. J Allergy Clin Immunol 2004; 113:
245-51.
[?zet]
-
Rabe
KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM, Atienza T, et al.
Budesonide/formoterol in a single inhaler for maintenance and relief in
mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129:
246-56.
[?zet] [Tam Metin] [PDF]
-
O?Byrne
PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al.
Budesonide/formoterol combination therapy as both maintenance and reliever
medication in asthma. Am J Respir Crit Care Med 2005; 171: 129-36.
[?zet] [Tam Metin] [PDF]
-
Scicchitano
R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centanni S, et al. Efficacy and
safety of budesonide/formoterol single inhaler therapy versus a higher dose of
budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20: 1403-18.
[?zet]
-
Vogelmeier
C, D?Urzo A, Pauwels R, Merino JM, Jaspal M, Boutet S, et al.
Budesonide/formoterol maintenance and reliever therapy: an effective asthma
treatment option? Eur Respir J 2005; 26: 819-28.
[?zet] [Tam Metin] [PDF]
-
Kuna
P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and
reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61: 725-36.
[?zet] [Tam Metin] [PDF]
-
Bousquet
J, Boulet LP, Peters MJ, Magnussen H, Quiralte J, Martinez-Aguilar NE, et al.
Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs.
high-dose salmeterol/fluticasone. Respir Med 2007; 101: 2437-46.
[?zet]
-
Nelson
JA, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden ER Jr. Effect of
long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998;
339: 141-6.
[?zet] [Tam Metin] [PDF]
-
Newnham
DM, McDevitt DG, Lipworth BJ. Bronchodilator subsensitivity after chronic
dosing with eformoterol in patients with asthma. Am J Med 1994; 97: 29-37.
[?zet]
-
Nelson
HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter
Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or
usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26.
[?zet] [Tam Metin] [PDF]
-
Israel
E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of
regularly scheduled albuterol treatment in asthma: genotype-stratified,
randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505-12.
[?zet]
-
Sullivan
P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Anti-inflammatory effects
of low-dose oral theophylline in atopic asthma. Lancet 1994; 343: 1006-8.
[?zet]
-
Kidney
J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by
theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir
Crit Care Med 1995; 151: 1907-14.
[?zet]
-
Barnes
PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med
2003; 167: 813-8.
[Tam Metin] [PDF]
-
Rivington
RN, Boulet LP, Cote J, Kreisman H, Small DI, Alexander M, et al. Efficacy of
Uniphyl, salbutamol, and their combination in asthmatic patients on high-dose
inhaled steroids. Am J Respir Crit Care Med 1995; 151(2 Pt 1): 325-32
[?zet]
-
Evans
DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of
low-dose inhaled budesonide plus theophylline and high- dose inhaled budesonide
for moderate asthma. N Engl J Med 1997; 337: 1412-8.
[?zet] [Tam Metin] [PDF]
-
Ukena
D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H, et al. Comparison
of addition of theophylline to inhaled steroid with doubling of the dose of
inhaled steroid in asthma. Eur Respir J 1997; 10: 2754-60.
[?zet] [PDF]
-
Davies
B, Brooks G, Devoy M. The efficacy and safety of salmeterol compared to
theophylline: meta- analysis of nine controlled studies. Respir Med 1998; 92:
256-63.
[?zet]
-
Wilson
AJ, Gibson PG, Coughlan J. Long acting beta-agonists versus theophylline for
maintenance treatment of asthma. Cochrane Database Syst Rev 2000; 2.
[?zet]
-
Ahn
HC, Lee YC. The clearance of theophylline is increased during the initial
period of tuberculosis treatment. Int J Tuberc Lung Dis 2003; 7: 587-91.
[?zet]
-
Humbert
M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of
omalizumab as add-on therapy in patients with severe persistent asthma who are
inadequately controlled despite best available therapy (GINA 2002 step 4
treatment): INNOVATE. Allergy 2005; 60: 309-16.
[?zet] [Tam Metin] [PDF]
-
Milgrom
H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, et al. Treatment of
allergic asthma with monoclonal anti-IgE antibody. rhuMAb- E25 Study Group. N
Engl J Med 1999; 341: 1966-73.
[?zet] [Tam Metin] [PDF]
-
Busse
W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab,
anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe
allergic asthma. J Allergy Clin Immunol 2001; 108: 184-90.
[?zet]
-
Molimard
M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the
first patients treated in real-life practice in France. Respir Med 2008; 102:
71-6.
[?zet]
-
Miller
CW, Krishnaswamy N, Johnston C, Krishnaswamy G. Severe asthma and the
omalizumab option. Clin Mol Allergy 2008; 20; 6: 4.
[?zet] [Tam Metin] [PDF]
-
Mash
B, Bheekie A, Jones PW. Inhaled vs. oral steroids for adults with chronic
asthma. Cochrane Database Syst Rev 2000; 2.
[?zet]
-
Toogood
JH, Baskerville J, Jennings B, Lefcoe NM, Johansson SA. Bioequivalent doses of
budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol
1989; 84(5 Pt 1): 688-700.
[?zet]
-
Recommendations
for the prevention and treatment of glucocorticoid- induced osteoporosis.
American College of Rheumatology Task Force on Osteoporosis Guidelines.
Arthritis Rheum 1996; 39: 1791-801.
-
Campbell
IA, Douglas JG, Francis RM, Prescott RJ, Reid DM. Five year study of etidronate
and/or calcium as prevention and treatment for osteoporosis and fractures in
patients with asthma receiving long term oral and/or inhaled glucocorticoids.
Thorax 2004; 59: 761-8.
[?zet] [Tam Metin] [PDF]
-
Eastell
R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, et al. A UK Consensus
Group on management of glucocorticoid-induced osteoporosis: an update. J Intern
Med 1998; 244: 271-92.
[?zet] [Tam Metin] [PDF]
-
Guillevin
L, Pagnoux C, Mouthon L. Churg-strauss syndrome. Semin Respir Crit Care Med
2004; 25: 535-45.
[?zet]
-
Rabe
KF, Adachi M, Lai CKW, et al. Worldwide severity and control of asthma in
children and adults: the global asthma insights and reality surveys. J Allergy
Clin Immunol 2004; 114: 40-47.
[?zet]
-
Sekerel
BE, Gemicioglu B, Soriano JB. Asthma insights and reality in Turkey (AIRET)
study. Respir Med 2006; 100: 1850-4.
[?zet]
-
Bateman
ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can
guideline-defined asthma control be achieved? The Gaining Optimal Asthma
Control Study. Am J Respir Crit Care Med 2004; 170: 836-44.
[?zet] [Tam Metin] [PDF]
-
Nathan
RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of
the asthma control test: a survey for assessing asthma control. J Allergy Clin
Immunol 2004; 113: 59-65.
[?zet]
-
Juniper
EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version
of the asthma quality of life questionnaire. Chest 1999; 115: 1265-70.
[?zet] [Tam Metin] [PDF]
-
Juniper
EF, Bousquet J, Abetz L, Bateman ED. Identifying ?well-controlled? and ?not
well-controlled? asthma using the Asthma Control Questionnaire. Respir Med
2005.
-
Juniper
EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of
three shortened versions of the asthma control questionnaire. Respir Med 2005;
99: 553-8.
[?zet]
-
Vollmer
WM, Markson LE, O?Connor E, Sanocki LL, Fitterman L, Berger M, et al.
Association of asthma control with health care utilization and quality of life.
Am J Respir Crit Care Med 1999; 160(5 Pt 1): 1647-52.
[?zet] [Tam Metin] [PDF]
-
[No
authors listed]. Using beta 2-stimulants in asthma. Drug Ther Bull 1997; 35:
1-4.
-
O?Byrne
PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et
al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the
OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164(8 Pt 1): 1392-7.
[?zet] [Tam Metin] [PDF]
-
Adams
NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW. Inhaled beclomethasone versus
placebo for chronic asthma. Cochrane Database Syst Rev 2005(1): CD002738.
[?zet]
-
Drazen
JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the
leukotriene pathway. N Engl J Med 1999; 340: 197-206.
-
Deykin
A, Wechsler ME, Boushey HA, Chinchilli VM, Kunselman SJ, Craig TJ, et al.
Combination therapy with a long-acting -agonist and a leukotriene
antagonist in moderate asthma. Am J Respir Crit Care Med 2007; 175: 228-34.
[?zet] [Tam Metin] [PDF]
-
Pauwels
RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect
of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and
Corticosteroids, Establishing Therapy (FACET) International Study Group. N Engl
J Med 1997; 337: 1405-11.
[Tam Metin] [PDF]
-
Lofdahl
CG, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF, et al. Randomised, placebo
controlled trial of effect of a leukotriene receptor antagonist, montelukast,
on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319:
87-90.
[?zet] [Tam Metin] [PDF]
-
Price
DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, et al. Randomised
controlled trial of montelukast plus inhaled budesonide versus double dose
inhaled budesonide in adult patients with asthma. Thorax 2003; 58: 211-6.
[?zet] [Tam Metin] [PDF]
-
Fish
JE, Israel E, Murray JJ, Emmett A, Boone R, Yancey SW, et al. Salmeterol powder
provides significantly better benefit than montelukast in asthmatic patients
receiving concomitant inhaled corticosteroid therapy. Chest 2001; 120: 423-30.
[?zet] [Tam Metin] [PDF]
-
Evans
DJ, Taylor DA, Zetterstrom O, Chung KF, O?Connor BJ, Barnes PJ. A comparison of
low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide
for moderate asthma. N Engl J Med 1997; 337: 1412-8.
[?zet] [Tam Metin] [PDF]
-
O'Byrne
PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al.
Budesonide/formoterol combination therapy as both maintenance and reliever
medication in asthma. Am J Respir Crit Care Med 2005; 171: 129-36.
[?zet] [Tam Metin] [PDF]
-
Scicchitano
R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centanni S, et al. Efficacy and
safety of budesonide/formoterol single inhaler therapy versus a higher dose of
budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20: 1403-18.
[?zet]
-
Rabe
KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM, Atienza T, et al.
Budesonide/formoterol in a single inhaler for maintenance and relief in
mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129:
246-56.
[?zet] [Tam Metin] [PDF]
-
Vogelmeier
C, D?Urzo A, Pauwels R, Merino JM, Jaspal M, Boutet S, et al.
Budesonide/formoterol maintenance and reliever therapy: an effective asthma
treatment option? Eur Respir J 2005; 26: 819-28.
[?zet] [Tam Metin] [PDF]
-
Szefler
SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al.
Significant variability in response to inhaled corticosteroids for persistent
asthma. J Allergy Clin Immunol 2002; 109: 410-8.
[?zet]
-
Powell
H, Gibson PG. Inhaled corticosteroid doses in asthma: an evidence-based
approach. Med J Aust 2003; 178: 223-5.
[?zet]
-
Vaquerizo
MJ, Casan P, Castillo J, Perpina M, Sanchis J, Sobradillo V, et al. Effect of
montelukast added to inhaled budesonide on control of mild to moderate asthma.
Thorax 2003; 58: 204-10.
[?zet] [PDF]
-
Virchow
JC, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma
control in patients receiving highdose inhaled corticosteroids. Am J Respir
Crit Care Med 2000; 162(2 Pt 1): 578-85.
[?zet] [Tam Metin] [PDF]
-
Tamaoki
J, Kondo M, Sakai N, Nakata J, Takemura H, Nagai A, et al. Leukotriene antagonist
prevents exacerbation of asthma during reduction of high-dose inhaled
corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit
Care Med 1997; 155: 1235-40.
[?zet]
-
Mash
B, Bheekie A, Jones PW. Inhaled vs oral steroids for adults with chronic
asthma. Cochrane Database Syst Rev 2000; 2.
[?zet]
-
Milgrom
H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, et al. Treatment of
allergic asthma with monoclonal anti-IgE antibody. rhuMAb- E25 Study Group. N
Engl J Med 1999; 341: 1966-73.
[?zet] [Tam Metin] [PDF]
-
Humbert
M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of
omalizumab as add-on therapy in patients with severe persistent asthma who are
inadequately controlled despite best available therapy (GINA 2002 step 4
treatment): INNOVATE. Allergy 2005; 60: 309-16.
[?zet] [Tam Metin] [PDF]
-
Djukanovic
R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of
treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation
in allergic asthma. Am J Respir Crit Care Med 2004; 170: 583-93.
[?zet] [Tam Metin] [PDF]
-
Reddel
H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma
exacerbations and poor asthma control. Lancet 1999; 353: 364-9.
[?zet]
-
Hawkins
G, McMahon AD, Twaddle S, Wood SF, Ford I, Thomson NC. Stepping down inhaled
corticosteroids in asthma: randomised controlled trial. BMJ 2003; 326: 1115.
[?zet] [Tam Metin] [PDF]
-
Powell
H, Gibson PG. Initial starting dose of inhaled corticosteroids in adults with
asthma: a systematic review. Thorax 2004; 59: 1041-5.
[?zet] [Tam Metin] [PDF]
-
Powell
H, Gibson PG. High dose versus low dose inhaled corticosteroid as initial
starting dose for asthma in adults and children. Cochrane Database Syst Rev
2004: CD004109.
[?zet]
-
Boulet
LP, Drollmann A, Magyar P, Timar M, Knight A, Engelstatter R, et al.
Comparative efficacy of once-daily ciclesonide and budesonide in the treatment
of persistent asthma. Respir Med 2006; 100: 785-94.
[?zet]
-
Masoli
M, Weatherall M, Holt S, Beasley R. Budesonide once versus twice-daily
administration: meta-analysis. Respirology 2004; 9: 528-34.
[?zet]
-
Bateman
ED, Fairall L, Lombardi DM, English R. Budesonide/formoterol and formoterol
provide similar rapid relief in patients with acute asthma showing
refractoriness to salbutamol. Respir Res 2006; 7: 13.
[?zet] [Tam Metin] [PDF]
-
FitzGerald
JM, Boulet LP, Follows R, M.A. CONCEPT: a one year, multi centre, randomized
double blind, double-dummy comparison of salmeterol/fluticasone propionate
using a stable dosing regimen with formoterol/budesonide using an adjustable
maintenance regimen in adults with persistent asthma. Clinical Therapeutics
2005; 27: 1-14.
-
Reddel
HK, Barnes DJ. Pharmacological strategies for selfmanagement of asthma
exacerbations. Eur Respir J 2006; 28: 182-99.
[?zet] [Tam Metin] [PDF]
-
Strek
ME. Difficult asthma. Proc Am Thorac Soc 2006; 3: 116-23.
[?zet] [Tam Metin] [PDF]
-
Friedman
NJ, Zeiger RS. The role of breast feeding in the development of allergy and
asthma. J Allergy Clin Immunol 2005; 115: 1238-48.
[?zet]
-
Gdalevich
M, Mimouni D, Mimouni M. Breast-feeding and the risk of bronchial asthma in
childhood: a systematic review with meta-analysis of prospective studies. J
Pediatr 2001; 139: 261-6.
[?zet]
-
Mimouni
BA, Mimouni D, Mimouni M, Gdalevich M. Does breast-feeding protect against
allergic rhinitis during childhood? A meta-analysis of prospective studies.
Acta Paediatr 2002; 91: 275-9.
[?zet]
-
Custovic
A, Simpson BM, Simpson A, Kissen P, Woodcock A. Effect of environmental
manipulation in pregnancy and early life: effect on respiratory symptoms and
atopy during the first year of life: a randomised trial. Lancet 2001; 358:
188-93.
[?zet]
-
Horak
F Jr, Matthews S, Ihorst G, Arshad SH, Frischer T, Kueht J, et al. Effect of
mite impermeable mattress encasings and an educational package on the
development of allergies in a multinational randomized, controlled birth cohort
study-24 months results of teh Study of Prevention of Allergy in Children in
Europe. Clin Exp Allergy 2004; 34: 1220-5.
[?zet]
-
van
Strien RT, Koopman LP, Kerkhop M, Oldenwening M, de Jongste JC, Gerritsen J, et
al. Mattress encasings and mite allergen levels in the Prevention and Incidence
of Asthma and Mite Allergy study. Clin Exp Allergy 2003; 33: 490-5.
[?zet]
-
Marks
GB. What should we tell allergic families about pets? J Allergy Clin Immunol
2001; 108: 500-2.
-
Remes
ST, Castro-Rodriguez JA, Holberg CJ, Martinez FD, Wright AL. Dog exposure in
infancy decreases the subsequent risk of frequent wheeze but not of atopy. J
Allergy Clin Immunol 2001; 108: 509-15.
[?zet]
-
Lau
S, Illi S, Sommerfeld C, Niggemann B, Bergmann R, von Mutius E, et al. Early
exposure to house-dust mite and cat allergens and development of childhood
asthma: a cohort study. Multicentre Allergy Study Group. Lancet 2000; 356:
1392-7.
[?zet]
-
Ownby
DR, Johnson CC, Peterson EL. Exposure to dogs and cats in the first year of
life and risk of allergic sensitization at 6 to 7 years of age. JAMA 2002; 288:
963-72.
[?zet] [Tam Metin] [PDF]
-
Jaakkola
JJ, Gissler M. Maternal smoking in pregnancy, fetal development and childhood
asthma. Am J Public Health 2004; 94: 136-40.
[?zet] [Tam Metin] [PDF]
-
Arshad
SH. Primary prevention of asthma and allergy. J Allergy Clin Immunol 2005; 116:
3-14.
[?zet]
-
ETAC
Study Group. Allergic factors associated with the development of asthma and the
influence of cetirizine in a double-blind, randomized, placebo-controlled
trial: first results of ETAC. Pediatr Allergy Immunol 1998; 9: 116-24.
[?zet]
-
M?ller
C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reducas the development
of asthma in children with seasonal rhinoconjunctivitis (the PAT study). JACI
2002; 109: 251-6.
[?zet]
-
Kalpaklioglu
F, Emekci M, Ferizli AG, Misirligil Z. On behalf of the House Dust Mite Working
Group. A survey of acarofauna in Turkey: comparison of seven different
geographic regions . Allergy Asthma Proc 2004; 25: 185-90.
[?zet]
-
Woodcock
A, Forster L, Matthews E, Martin J, Letley L, Vickers M, et al. Control of
exposure to mite allergen and allergen impermeable bed covers for adults with
asthma. N Engl J Med 2003; 349: 225-36.
[?zet] [Tam Metin] [PDF]
-
Halken
S, Host A, Niklassen U, Hansen LG, Nielsen F, Pedersen S, et al. Effect of
mattress and pillow encasings on children with asthma and house dust mite
allergy. JACI 2003; 111: 169-76.
[?zet]
-
Gotzsche
PC, Hammarquist C, Burr ML. House dust mite control measures in the management
of asthma: meta-analysis. BMJ 1998; 317; 1105-10.
[?zet] [Tam Metin] [PDF]
-
Gotzsche
PC, Johansen HK, Schmidt LM, Burr ML. House dust mite control measures for
asthma. Cochrane Database Syst Rev 2004; 4: CD001187.
[?zet]
-
Bj?rnsdottir
US, Jakobinudottir S, Runarsdottir V, Juliusson S. The effect of reducing
levels of cat allergen (Fel d 1) on clinical symptoms in patients with cat
allergy. Ann Allergy Asthma Immunol 2003; 91: 189-94.
[?zet]
-
Moira
CY, Ferguson A, Dimich-Ward H, Watson W, Manfreda J, Becker A. Effectiveness
and compliance to intervention measures in reducing house dust and cat allergen
levels. Ann Allergy Asthma Immunol 2002; 88: 52-8.
[?zet]
-
Carswell
F, Oliver J, Weeks J. Do mite avoidance measures affect mite and cat airborne
allergens? Clin Exp Allergy 1999; 29: 193-200.
[?zet]
-
Krieger
J, Takaro TK, Allen C, Song L, Weaver M, Chai S, et al. The Seattle-King County
Healthy Homes Project: Implementation of a Comprehensive Approach to Improving
Indoor Environmental Quality for Low-Income Children with Asthma. Environ
Health Perspect 2002; 110(Suppl 2): 311-22.
[?zet] [PDF]
-
Burr
ML, Matthews IP, Arthur RA, Watson HL, Gregory CJ, Dunstan FD, et al. Effects
on patients with asthma of eradicating visible indoor mould: a randomised
controlled trial. Thorax 2007; 62: 767-72
[?zet] [Tam Metin] [PDF]
-
Morgan
WJ, Crain EF, Gruchalla RS, O?Connor GT, Kattan M, Evans R, et al. Results of a
home-based environmental intervention among urban children with asthma. N Engl
J Med 2004; 351: 1068-80.
[?zet] [Tam Metin] [PDF]
-
Eggleston
PA, Butz A, Rand C, Curtin-Brosnan J, Kanchanaraksa S, Swartz L, et al. Home
environmental intervention in inner-city asthma: a randomized controlled
clinical trial. Ann Allergy Asthma Immunol 2005; 95: 518-24.
[?zet]
-
Kunzli
N, Kaiser R, Medina S, Studnicka M, Chanel O, Filliger P, et al. Public-health
impact of outdoor and traffic-related air pollution: a European assessment.
Lancet 2000; 356: 795-801.
[?zet]
-
Stein
MD, Weinstock MC, Herman DS, Anderson BJ. Respiratory symptom relief related to
reduction in cigarette use. J Gen Intern Med 2005; 20: 889-94.
[?zet] [Tam Metin] [PDF]
-
Rachiotis
G, Savani R, Brant A, Mac Neill SJ, Newman-Taylor A, Cullinan P. Outcome of
occupational asthma after cessation of exposure: a systematic review Thorax
2007; 62: 147-52.
[?zet] [Tam Metin] [PDF]
-
Cates
CJ, Jefferson TO, Bara AI, Rowe BH. Vaccines for preventing influenza in people
with asthma (Cochrane Review). Cochrane Database Syst Rev 2000: CD000364.
[?zet]
-
Abadoglu
O, Mungan D, Pasao?lu G, Cel?k G, Misirligil Z. Influenza vaccination in
patients with asthma: effect on the frequency of upper respiratory tract
infections and exacerbations. J Asthma 2004; 41: 279-83.
[?zet]
-
Rodrigo
GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest 2004; 125:
1081-102.
[?zet] [Tam Metin] [PDF]
-
Miles
JF, Garden GM, Tunnicliffe WS, Cayton RM, Ayres JG. Psychological morbidity and
coping skills in patients with brittle and non-brittle asthma: a case control
study. Clin Exp Allergy 1997; 27: 1151-9.
[?zet]
- Bavbek
S, Celik G, Demirel YS, Misirligil Z. Risk factors associated with
hospitalizations for asthma attacks in Turkey. Allergy Asthma Proc 2003; 24:
437-42.
[?zet]
-
Folkerts
G, Buse WW, Nijkamp FP, Sorkness R, Gern JE. Virus-induced airway
hyperresponsiveness and asthma. Am J Respir Crit Care Med 1998; 157: 1708-20.
[Tam Metin] [PDF]
-
Green
RM, Custovic A, Sanderson G, Hunter J, Johnston SL, Woodcock A. Synergism
between allergens and viruses and risk of hospital admission with asthma:
case-control study. BMJ 2002; 324: 763.
[?zet] [Tam Metin] [PDF]
-
Ramnath
VR, Clark S, Camargo CA Jr. Multicenter study of clinical features of
sudden-onset versus slower-onset asthma exacerbations requiring
hospitalization. Respir Care 2007; 52: 1013-20.
[?zet] [PDF]
-
Mc
Fadden ER. Acute severe asthma. Am J Respir Crit Care Med 2003; 168: 740-59.
-
Crompton
GK. Management of severe asthma. In: Barnes PJ (ed). Asthma, Basic Mechanisms
and Clinical Management. 3rd ed. London: Academic Press, 1998:
821-34.
-
Janson
C, Boe J, Crompton GK. Acute asthma. Eur Respir J 2000; 10: 503-6.
-
Romagnoli
M, Caramori G, Braccioni F, Ravenna F, Barreiro E, Siafakas NM, et al.
Near-fatal asthma phenotype in the ENFUMOSA Cohort. Clin Exp Allergy 2007; 37:
552-7.
[?zet]
-
Aldington
S, Beasley R. Asthma exacerbations: assessment and management of severe asthma
in adults in hospital. Thorax 2007; 62: 447-58.
[?zet] [Tam Metin] [PDF]
-
Bel
EH. Management of the acute exacerbation and emergency treatment of asthma. In:
Holgate ST, Boushey HA, Fabbri LM (eds). Difficult Asthma. London: Martin
Dunitz Ltd., 1999: 227-91.
-
Oguzulgen
IK, Turktas H, Mullaoglu S, Ozkan S. What can predict the exacerbation severity
in asthma? Allergy Asthma Proc 2007; 28: 1-4.
-
Travers
A, Jones AP, Kelly K, Barker SJ, Camargo CA, Rowe BH. Intravenous
beta2-agonists for acute asthma in the emergency department. Cochrane Database
Syst Rev 2001; CD002988.
[?zet]
-
Cairns
CB. Acute asthma exacerbations: phenotypes and management. Clin Chest Med 2006;
27: 99-108.
[?zet]
-
Rowe
BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for
preventing relapse following acute exacerbations of asthma. Cochrane Database
Syst Rev 2007; 18: CD000195.
[?zet]
-
Reddel
HK, Barnes DJ. Pharmacological strategies for self-management of asthma
exacerbations. Review. Eur Respir J 2006; 28: 182-99.
[?zet] [Tam Metin] [PDF]
-
FitzGerald
JM, Gibsob PG. Asthma exacerbations-4: prevention. Thorax 2006; 61: 992-9.
[?zet] [Tam Metin] [PDF]
-
Inwald
D, Roland M, Kuitert L, McKenzie SA, Petros A. Oxygen treatment for acute
severe asthma. BMJ 2001; 323: 98-100.
[Tam Metin] [PDF]
-
Rowe
BH, Edmonds ML, Spooner CH, Camargo CA. Evidence-based treatments for acute
asthma. Respir Care 2001; 46: 1380-90.
[?zet]
-
Rodrigo
GJ, Castro J. Anticholinergics in the treatment of children and adults with
acute asthma: a Systematic review with meta-analysis. Thorax 2005: 60: 740-6.
[?zet] [PDF]
-
Rodrigo
GJ, Rodrigo C. Triple inhaled drug protocol for the treatment of acute severe
asthma. Chest 2003; 123: 1908-15.
[?zet] [Tam Metin] [PDF]
-
Sherman
MS, Verceles AC, Lang D. Systemic steroids for the treatment of acute asthma.
Where do we stand? Clin Pulmonary Medicine 2006; 13: 315-20.
-
Rodrigo
GJ, Rodrigo C. Corticosteroids in the emergency department therapy of acute
adult asthma: an evidenced based evaluation. Chest 1999; 116: 285-95.
[?zet] [Tam Metin] [PDF]
-
Manser
R, Reid D, Abramson M. Corticosteroids for acute severe asthma in hospitalised
patients (Review). Cochrane Database Syst Rev 2007.
-
Beasley
R, Aldington S. Magnesium in the treatment of asthma. Curr Opin Allergy Clin
Immunol 2007; 7: 107-10.
[?zet]
-
Bitz
M, Blitz S, Beasley R, Diner BM, Hughes R, Knopp JA, et al. Inhaled magnesium
sulfate in the treatment of acute asthma. Cochrane Database Syst Rev 2005;
CD003898.
[?zet]
-
Bradshaw
TA, Matusiewicz SP, Crompton GK, Innes JA, Greening AP. Intravenous magnesium
sulfate provides no additive benefit to standart management in acute asthma.
Respir Med 2007.
-
Rowe
BH, Camargo CA. The use of magnesium sulfate in acute asthma: rapid uptake of
evidence in North American emergency departments. J Allergy Clin Immunol 2006;
117: 53-8.
[?zet]
-
Kokturk
N, Turktas H, Kara P, Mullaoglu S, Yilmaz F, Karamercan A. A randomized
clinical trial of magnesium sulphate as a vehicle for nebulized salbutamol in
the treatment of moderate to severe asthma attacks. Pulmonary Pharmacology and
Therapeutics 2005; 18: 416-21.
[?zet]
-
Tapp
S, Lasserson TJ, Rowe B. Education interventions for adults who attend the
emergency room for acute asthma. Cochrane Database Syst Rev. 2007; 18:
CD003000. DOI: 1002/14651858. CD003000.pub2.
[?zet]
-
Foster
JM, Hoskins G, Smith B, Lee AJ, Price D, Pinnock H. Practice development plans
to improve the primary care management of acute asthma: randomised controlled
trial. BMC Fam Pract 2007 24; 8: 23.
[?zet] [Tam Metin] [PDF]
-
Canadian
Asthma Consensus Report, CMAJ 1999; 161: 30: 11.
-
British
Guideline on Management of Asthma, British Thoracic Society Scottish
Intercollegiate Guidelines Network Revised Edition 2005.
-
Mungan
D. Cooccurrence of asthma and rhinitis. Ankara: Poyraz T?bbi Yay?nc?l?k, 2007;
7: 3.
-
Karada?
F, ?ilda? O, Pirim C, et al. Frequency of paranasal sinus pathologies and its
association with serum eosinophil concentration and IgE levels in asthma. AD?
T?p Fak?ltesi Dergisi 2001; 2: 9-12.
[?zet] [PDF]
-
Nuho?lu
Y, ??can M. Nuho?lu ?, et al. Nasal and paranasal sinus tomography findings in
asthmatic children with chronic rhitis and recurren sinusites. T?rkiye
Klinikleri Allerji-Ast?m Dergisi 2001;3:18-22
[?zet]
-
Pata
YS, Bicik E, Aygen? E, et al. Late consequences of endoscopic sinus surgery.
T?rkiye Klinikleri K.B.B dergisi 2003; 3: 9-15.
[?zet]
-
Dursun
E, Samim E, Korkmaz H, et al. Endoscopic sinus surgery in patients with nasal
poliposis. Kulak Burun Bo?az ve Ba? Boyun Cerrahisi Dergisi 1998; 602: 71-80.
[?zet] [PDF]
-
?zcan
M, Altu? H?, Olcay I et al. Oral corticosteroid use in the treatment of nasal
poliposis. Kulak Burun Bo?az ve Ba? Boyun Cerrahisi Dergisi 2000; 8: 83-8.
[?zet] [PDF]
-
?zkurt
S, Zencir M, Hac?o?lu M, et al. Frequency of occupational asthma auto?
painters. Solunum Dergisi 2003; 5: 49-53.
[?zet] [PDF]
-
U?gun
?, ?zdemir N, Metinta? M, et al. Frequency of occupational asthma in auto? and
furniture painters. Solunum Hastal?klar? Dergisi 1999; 10: 126-30.
-
Turgut
T, Ta?demir C, Muz H, et al. Frequency of occupational asthma in auto? and
furniture painters in central Elazig. Tuberk Toraks 2005; 53: 371-8.
[?zet] [PDF]
-
??mr?n
A, Akp?nar M. Furnisher asthma (two cases). Solunum Hastal?klar? 1997; 8:
99-102.
-
Y?lmaz
V, K?l??aslan Z, ?lker O, et al. Pulmonary function parameters in auto
painters. Solunum 1987; 12: 220-3.
-
Fi?ek?i
F, K?l??aslan Z. Pulmonary symptoms and prick test findings in furniture
painting workers. Solunum Hastal?klar?. 1998; 9: 143-53.
-
K?l??aslan
Z, Erkan F, Ece T, et al. Baker?s asthma and flour sensitivity in a modern
bakery. Solunum 1990; 15: 446-51.
-
Top?u
F, Yorganc?o?lu A, ??mr?n AH, ?elik P. Occupational asthma prevalence in bakery
workers. 25.Y?l Akci?er G?nleri Kongre Kitab? 2000; 332-41.
-
Yorganc?o?lu
A, ?akar A, Keskin T, Din? G, ?elik P. Respiratory symptoms and occupational
asthma in polyurethane foam producers. Turkish Respiratory Journal 2001; 3: 19-23.
-
Akp?nar
M, ?elikten E, ??mr?n A. Occupational asthma prevalence and risk factors in
hairdressers in ?zmir. Solunum Hastal?klar? 1998; 9: 261-8.
-
G?lmez
?, ?etinkaya F, Oymak FS, et al. Occupational asthma among hairdresser?s
apprentices. Eur Respir J 1998; 12(Suppl 28): S333.
-
?zesmi
M, Aslan H. COPD in carpet weavers. Solunum 1984; 9: 260-5.
-
K?l??aslan
Z, Y?lmaz V, ??kr?k??o?l? S, et al. Pulmonary function impairment in cotton
textile workers. Solunum 1987; 12: 242-6.
-
G?ven
K, ?zesmi M, Demir R. Occupational asthma and wool dust. Solunum 1992; 17:
228-35.
-
G?rg?ner
M, Mirici A, Girgi? M, et al. Pulmonary symptoms and occupational asthma
prevalence in Atat?rk University Carpet Education Centre workers. Solunum 1995;
20: 259-65.
-
?ahin
?, Akkaya A. Pulmonary symptoms and pulmonary function tests in cotton yarn
factory workers. Solunum Hastal?klar? 1998; 9: 129-42.
-
Er
M, Emri S, Karakoca Y, Bar?? Y?. Bissinosis and COPD prevalence in jute yarn
factory workers. Toraks Derne?i 2. Kongresi Bildiri ?zet Kitab?. Antalya: 1998;
85.
-
Zencir
M, Elci OC, Ucku R, Cimrin AH. Prevalence of bysinosis among textile workers.
Eur Respir J 1996; 9(Suppl 23): 178.
-
Erdo?an
S, G?lmez ?,?nl?hizarc? K, et al. Occupational asthma prevalence and pulmonary
functions in workers exposed to wood dust. Solunum 1995; 19: 127-34.
-
?uhadaro?lu
?, K?l??aslan Z, Alzafer S, et al. ?stanbul T?p Fak?ltesi ?al??anlar?nda Latex
glove allergy in ?stanbul Univesity School of Medicine staff. Solunum 1995; 19:
147-50.
-
Ard??
S, ?zdemir N, Cingi M, et al. A new occupational asthma due to morphine powder.
Solunum Hastal?klar? 1990; 1: 37-50.
-
K?l??aslan
Z, Ya?a M. Bronchial asthma associated with detergent enzyme. Eur Respir J
1992; 5(Suppl 15): S405.
-
Demirel
M, G?lmez ?, Oymak S, Demir R, ?zesmi M. Occupational asthma in glass workers.
T?rkiye Solunum Ara?t?rmalar? Derne?i XXV. Ulusal Kongresi, ?stanbul. ?zet
Kitab?: SB 044.
-
Odaba??
A, Akp?nar M, ?elikten E, El?i ?, Perim K, B?y?k?irin M. Occupational asthma
flower sellers. T?rkiye Solunum Ara?t?rmalar? Derne?i XXV. Ulusal Kongresi,
?stanbul. ?zet Kitab?: P 007.
-
?akar
A, Kaya E, ?elik P, Gencer N, Temel O, Yaman N, et al. Silikosis in ceramic
factory workers. Tuberk Toraks 2005; 53: 148-55.
[?zet] [PDF]
-
Temel
O, ?akar Co?kun A, Yaman N, Sar?o?lu N, Alka? ?, Konyar I, et al. Occupational
asthma in welders and painters. World Asthma Meeting 2007 ?stanbul, Abstract
,64.
-
Demir
AU, Karakaya G, Kalyoncu AF. Allergy symptoms and IgE immune response to rose:
an occupational and environmental disease. Allergy 2002; 57: 936-9.
[?zet] [Tam Metin] [PDF]
-
Tutluoglu
B, Ati?, Anakkaya AN, Altug E, Tosun GA, Yaman M. Sensitization to horse hair,
symptoms and lung function in grooms. Clin Exp Allergy 2002; 32: 1170-3.
[?zet]
-
Atis
S, Tutluoglu B, Sahin K, Yaman M, K???kusta AR, Oktay I. Sensitization to
sunflower pollen and lung functions in sunflower processing workers. Allergy
2002; 57: 35-9.
[?zet] [Tam Metin] [PDF]
-
Gem
JE, Lemanske RF. Infectious triggers of pediatric asthma. Pediatr Clin North Am
2003; 50: 555-75.
[?zet]
-
Johston
SL. Viruses and asthma. Allergy 1998; 53: 922-32.
-
Kraft
M. The role of bacterial infections in asthma. Clin Chest Med 2000; 21: 301-13.
[?zet]
-
Weiss
ST, Tager IB, Munoz A, Speizer FE. The relation of respiratory infections in
early in early childhood to the occurrence of increased levels of bronchial
responsiveness and atopy. Am Rev Respir Dis 1985; 131: 573-8.
[?zet]
-
Buse
WW. Respiratory infections: their role in airway responsiveness and
pathogenesis of asthma. J Allergy Clin Immunol 1990; 85: 671-83.
[?zet]
-
Edwards
MR, Kabadze T, Johnson MW, Ohston SL. New treatment regimes for virus induced
exacerbation of asthma. Pulmonary Pharmacology and Therapeutics 2006; 19:
320-34.
[?zet]
-
Harding
SM. Acid reflux and asthma. Curr Opin Pulm Med 2003; 9: 42-5.
[?zet]
-
Sontag
SJ. Why do the published data fail to clarify the relation between
gastroesophageal reflux and asthma? Am J Med 2000; 108: 159-69.
[?zet]
-
Diette
GB, Krishnan JA, Dominici F, Haponik E, Skinner EA, Steinwachs D, et al. Asthma
in olders patients. Factors associated with hospitalization. Arch Intern Med
2002; 162: 1123-32.
[?zet] [Tam Metin] [PDF]
-
Kiljendar
TO, Salomoa ER, Hietanen EK, Terho EO. Gastroesophageal reflux in asthmatics. A
double blind, placebe controlled crossover study with omeprazole. Chest 1999;
116; 1257-64.
[?zet] [Tam Metin] [PDF]
-
Irwin
RS, Zawacki JK, Curley FJ, French CL, Hoffman PJ. Chronic cough as the sole
manifestation of gastroesophageal reflux. Am Rew Respir Dis 1989; 140;
1294-300.
[?zet]
-
Gibson
PG, Henry RL, Coughhlan JL. Gastrooesophageal reflux treatment for asthma in
adults and children. Cochrane Database Syst Rev 2003; 2: CD0011496.
[?zet]
-
Littne
MR, Leung WF, Ballard ED, Huang B, Sarma NK. Effect of 24 weeks of lansoprazole
theraphy on asthma symptoms, exacerbations, quality of life, and pulmonary
function in adult asthmatic patients with acid reflux symptoms. Chest 2005;
128: 1128-35.
[?zet] [Tam Metin] [PDF]
-
Harmanci
E, Entok E, Metintas M, Vardareli E, Elbek O. Gastroesophageal reflux in the
patiens with asthma. Allergol Immunopathol 2001; 29: 123-8.
[?zet]
-
Nelson
HS. Is gastroesophageal reflux worsening your patients with asthma. Am J Respir
Dis 1990; 11: 827-44.
-
Samter
M, Beers FR. Intolerance to aspirin. Clinical studies and consideration of its
pathogenesis. Ann Intern Med 1968; 68: 975-63.
-
Szczeklik
A, Stevenson DD. Aspirin induced asthma: advance in pathogenesis, diagnosis and
management. J Allergy Clin Immunol 2003; 111: 913-21.
[?zet]
-
Jenkins
C, Costello J, Hodge L. Systematic review of prevalence of asprin induced
asthma and its implications in clinical practice. BMJ 2004; 328: 434.
[?zet] [Tam Metin] [PDF]
-
Kalyoncu
AF, Karakoca Y, Demir AU, Alpar R, Shehu V, Coplu L, et al. Prevalance of
asthma and allergic disease in Turkish university students. Allergol
Immunopathol 1996; 24: 152-7.
[?zet]
-
Celik
G, Mungan D, Ozer F, Ediger D, Bavbek S, Sin B, et al. Clinical feature and
atopy profile in Turkish subjects with analgesic intolerance. J Asthma 2002;
39: 101-6.
[?zet]
-
Szczeklik
A, Nizankowskka E, Duplaga M. Natural history of asprin induced asthma. AIANE
Investigators. European Network on Asprin-Induced Asthma. Eur Respir J 2000:
16: 432-6.
[?zet]
-
Szczeklik
A, Sanak M, Nizankowska-Mogilnicka E, Kielbasa B. Asprin intolerance and the
cyclooxygenase-leukotriene patways. Curr Opin Pulm Med 2004; 10: 51-6.
[?zet]
-
Stevenson
DD. Diagnosis, prevention, and treatment of adverse reactions to asprin and
nonsteroidal anti-inflammatuary drugs. J Allergy Clin Immunol 1984; 74: 617-22.
[?zet]
-
Nasser
SM, Phister R, Christie PE, Sousa AR, Barker J, Schimitz-Schumann M, et al.
Inflammatory cell population in bronchial biopsies from asprine-sensitive
asthmatic subjects. Am Respir Crit Care Med 1996; 153: 90-6.
[?zet]
-
Sampson
AP, Cowburn AS, Sladek K, Adamek L, Nizankowska E, Szczeklik A, et al. Profound
overexpression of leukotriene C4 synthase in bronchial biopsies from
asprine-intolerant asthmatic patients. Int Arch Allergy Immunol 1997; 113:
355-7
-
Szczeklik
A, Sanak M. Genetic mechanismis in asprine-induced asthma. Am J Respir Crit
Care Med 2000; 161: 142-6.
[Tam Metin] [PDF]
-
Celik
G, Bavbek S, Misirligil Z, Melli M. Release of cysteinyl leukotrienes with
aspirin stimulation and the effect of prostaglandin E(2) on this release from
peripheral blood leucocytes in aspirin-induced asthmatic patients. Clin Exp
Allergy 2001; 31: 1615-22.
[?zet]
-
Dahlen
SE, Malstrom K, Nizankowska E, Dahlen B, Kuna P, Kowalski M, et al. Improvement
of asprin-intolerant asthma by montelukast, a leukotriene antagonist: a
randomized, double- blind, placebo-controlled trial. Am J Respir Crit Care Med
2002; 165: 9-15.
[?zet] [Tam Metin] [PDF]
-
Bavbek
S, Celik G, Pasaoglu G, Misirligil Z. Rofecoxib, as a safe alternative for
acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients.
J Invest Allergol Clin Immunol 2006; 16: 57-62.
[?zet] [PDF]
-
Bavbek
S, ?elik G, Ediger D, Mungan D, Demirel YS, Misirligil Z. The use of nimesulide
in patients with acetylsalicyclic acid and nonsteroid anti-inflamatory drug
intolerance. J Asthma 1999; 36: 657-63.
[?zet]
-
Bavbek
S, Celik G, Ozer F, Mungan D, Misirligil Z. Safety of selective COX-2
inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients:
comparison of nimesulide, meloxicam, and rofecoxib. J Asthma 2004; 41: 67-75.
[?zet]
-
Celik
G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D, et al. Tolerability of
selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic
intolerance. J Asthma 2005; 42: 127-31.
[?zet]
-
Bavbek
S, Dursun AB, Dursun E, Eryilmaz A, Misirligil Z. Safety of meloxicam min
aspirin-hypersensitive patients with asthma and/or nasal polyps. A
challenge-proven study. Int Arch Allergy Immunol 2006; 142: 64-9.
- [?zet]
Celik
G, Erkokal FO, Bavbek S, Dursun B, Misirligil Z. Long term use and tolerability
of cyclooxygenase- 2 inhibitors in patients with analgesic intolerance. Ann
Allergy Asthma Immunol 2005; 95: 33-7.
[?zet]
-
Drazen
JM. Asthma theraphy with agents preventing leukotriene synthesis or action.
Proc Assoc Am Physicias 1999; 111: 547-59.
[?zet]
Yaz??ma
Adresi (Address for Correspondence):
Dr.
F?sun YILDIZ,
Kocaeli ?niversitesi T?p Fak?ltesi,
G???s
Hastal?klar? Anabilim Dal?,
Umuttepe Merkez Yerle?kesi
41380
Umuttepe, KOCAEL? - TURKEY
e-mail:
fusun.yildiz@gmail.com
Yazd?r